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CHAPTER ONE 
GENERAL INTRODUCTION 
Human herpesviruses. Indication of herpesviruses causing human disease 
dates back to the early days of medicine when Hippocrates used the Greek word 
“herpes” to describe lesions that appeared to creep across the skin. The term herpes, 
however, was used ubiquitously to define several skin conditions. It was Vidal that 
proved a herpesvirus, herpes simplex virus (HSV), is the infectious agent responsible by 
conducting human-to-human transmission studies (1). Future experiments by Andrews 
and Carmichael showed that HSV could cause recurrent infections in adults with 
neutralizing antibodies, but it was Burnet and Williams that recognized HSV can 
establish a lifelong latent infection that can still cause herpetic lesions in the presence of 
external stimuli (2).  
All viruses classified under the Herpesviridae family have similar virion 
structures. Each virion is composed of a double stranded DNA genome packaged inside 
an icosahedral capsid. Surrounding the capsid is an amorphous proteinacious coat 
labeled the tegument layer that forms a scaffold between the capsid and the outer lipid 
envelope (Fig. 1). There are over 200 viruses that belong to the Herpesviridae family 
with only 8 known to primarily infect humans (3). The human herpesviruses belong to 
three different subfamilies (Alphaherpesvirinae, Betaherpesvirinae, and 
Gammaherpesvirina) based on biological properties. The Alphaherpesvirinae consist of 
HSV 1 and 2, and varicella-zoster virus (VZV), with a broad host range and short 
replication cycle. The Betaherpesvirinae include human cytomegalovirus (HCMV), 
human herpesvirus 6 (type A and B), and human herpesvirus 7, which have a narrow 
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host range and a long replication cycle. The last subfamily Gammaherpesvirinae, are 
composed of Epstein-Barr virus and Kaposi's sarcoma virus that have the most 
restricted host range.  
Although the rate of the replication varies between the subfamilies, they share a 
common life cycle. Infection is initiated upon attachment of viral glycoproteins to species 
specific cellular receptors. Fusion of the viral envelope with the host membrane at the 
plasma membrane or inside endocytic vesicles mediates entry of the capsid and the 
release of tegument proteins into the cytoplasm (4, 5). The tegument proteins modulate 
host cell immune responses, regulate host cell protein synthesis, and facilitate the 
transport of the nucleocapsid to the nucleus. Docking of the nucleocapsid to the nuclear 
pore releases viral DNA into the nucleus where tegument proteins trans-activate viral 
gene expression. This initiates the lytic gene cascade consisting of three major kinetic 
classes (immediate early, early, and late) which lead to the production of viral particles. 
Released infectious viral progeny are capable of establishing a life-long latent infection, 
which can be reactivated in response to various stimuli.  
HCMV clinical relevance. HCMV is an opportunistic pathogen that has spread 
worldwide. Primary infections occur through contact with infected blood and urine, or 
mucosal secretions. The seroprevalence rate in the United States hovers around 50%, 
but rates are significantly higher in under developed countries (6, 7). Infection of healthy 
individuals is usually mild and self-limiting, yet results in a life-long latent infection with 
periodic episodes of reactivation.  
 
3 
 
 
 
Primary infection or reactivation of HCMV presents a concern to the 
immunocompromised, such as AIDS patients and transplant recipients. The assault on 
CD4 lymphocytes by HIV leaves the immune system depleted and allows HCMV 
proliferation and dissemination, leading to retinitis, gastrointestinal disease, and  
pneumonitis (8). HCMV retinitis once accounted for 90% of AIDS related vision loss until 
the development of highly effective antiretroviral and anti-CMV therapies (9, 10). 
Unfortunately, low income countries have limited access to these drugs which leaves 
AIDS patients at risk for acquiring HCMV retinitis (11). Also at risk of HCMV disease are 
solid organ and hematopoietic stem cell transplant patients as a result of life-long 
immunosuppressive drug regimens. Infection and invasion of HCMV into tissues can 
cause pneumonia, hepatitis, encephalitis, and even death. Fortunately, ganciclovir, 
high-dose acyclovir, and valacyclovir treatment have been shown to prevent early onset 
HCMV disease in hematopoietic stem cell transplants (12-15). Delayed onset HCMV 
disease still presents a major problem for clinicians who have turned to monitoring 
patients long term through pp65 antigenemia and PCR testing (12, 16). 
HCMV infection is also a concern for pregnant mothers who can vertically 
transmit the virus to their child during pregnancy or childbirth. In developed countries, 
HCMV is the most common viral congenital infection with 0.2% to 2.5% of newborns 
being affected (17). Infected children can be symptomatic or asymptomatic at birth, but 
all are at risk of developing severe neurological abnormalities that cause mental 
retardation, microcephaly, seizures, and hearing loss. In fact, HCMV is the leading 
cause of non-genetic sensorineural hearing loss among infants (7, 18). Anti-viral 
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treatment is recommended and effective in symptomatic congenital HCMV cases, but 
an HCMV vaccine would address asymptomatic and in utero infections (19).  
HCMV virion structure and genome. HCMV is the largest known human 
herpesvirus. The diameter of a single virion ranges from 150- 200 nm, which houses a 
linear double stranded DNA (230 kbp). The genome contains a unique long (UL) and a 
unique short region (US), flanked by sets of internal repeats (TRL/IRL and IRS/TRS 
respectively). Inversion of the UL and US regions allows up to four different isoforms of 
the HCMV genome. The coding capacity of the laboratory strain AD169 genome is 
around 190 translated open reading frames (ORFs) which all show high similarity to 
clinical isolates (20, 21). However, the total number of translated ORFs can be as high 
as 750 when including small codons (<80) and alternative transcript start, stop and 
splice sites, thus demonstrating the complexity of HCMV infection (22). 
HCMV attachment and entry. The broad cell tropism of HCMV is an essential 
component to multi-organ spread and disease. Clinical strains of HCMV have the ability 
to infect epithelial cells, endothelial cells, fibroblasts, smooth muscle cells, monocytes, 
and macrophages. The proteoglycan heparin sulfate is found on the all of these cells 
and is the primary site of attachment for HCMV glycoproteins gB and gM/gN (23). Other 
cell surface receptors have been proposed (i.e. EGFR and PDGFR), however, 
neutralizing antibody against these ligands proved unsuccessful at preventing entry, 
alluding to the possibility of alternative entry pathways (24, 25). Integrins, specifically 
α2β1, α6β1, and αvβ3, have also been considered attachment sites. Studies using anti-
integrin antibodies inhibited entry, yet binding still occurred, suggesting integrins are 
involved in virus-cell membrane fusion (26). The location of the fusion step differs 
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depending on cell type. In fibroblasts, fusion takes place at the outer cell membrane, 
which involves the viral glycoproteins gH and gL (5, 27), but in epithelial and endothelial 
cells, gH/gL forms a complex with proteins pUL128, pUL130 and pUL131 to initiate a pH 
dependent fusion that occurs after endocytosis of the virus particle (4).  
Following fusion, viral tegument proteins are released into the cytoplasm of the 
cell to facilitate a productive infection. Some include viral proteins that can counteract 
the host antiviral response. TRS1 and IRS1 prevent the phosphorylation of eukaryotic 
translation initiation factor eIF-2alpha and the activation of RNase L, which blocks 
cellular protein synthesis (28).  Another viral mechanism of immune evasion is inhibiting 
antigen presentation. One of the most abundant tegument proteins, pp65, blocks the 
antigen processing of IE2 to avoid cytotoxic killing by CD8+ T cells (29), and degrade 
HLA class II molecules to prevent recognition by CD4+ T cells (30). Other capsid 
associated tegument proteins are responsible for mediating the transport of the 
nucleocapsid to the nuclear pore via microtubules. Docking of the capsid initiates 
release of the viral genome into the host cell nucleus.  
HCMV gene expression and replication. Once the HCMV genome enters the 
nucleus, it circularizes and localizes to nuclear domain 10 sites, where tegument 
proteins initiate the lytic gene cascade. Although transfection of viral DNA alone results 
in productive infection, infectivity substantially increases in the presence of viral 
transactivators, such as pp71 and pUL35 (31). The association between pp71 and 
pUL35 act cooperatively to stimulate the major immediate early promoter and begin lytic 
gene expression (32). The primary products of the major immediate early promoter are 
immediate early genes IE1-p72 and IE2-p86. These proteins are involved in a variety of 
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functions, including evasion of host innate immunity, regulation of the cell cycle, and 
transactivation of viral and host genes (33-35). Although only IE2 is essential for 
replication (36), both IE1 and IE2 work synergistically with other viral and cellular 
components to drive early gene expression (37, 38).  
Early genes are the second kinetic class of genes expressed during a lytic 
infection and are required for viral DNA replication. HCMV DNA synthesis follows the 
assembly of viral and cellular proteins at the origin of lytic replication, termed oriLyt. To 
date, 11 viral genes are associated with oriLyt replication: UL44 (DNA processivity 
factor), UL54 (DNA polymerase), UL57 (single stranded-DNA-binding protein), UL70 
(primase), UL84 (replication initiator protein), UL102 (primase-associated factor), UL105 
(helicase), IRS1/TRS1, and UL36–38, UL112/113, and IE2 (39-41). Localization of 
UL84 and IE2 to replication centers initiates oriLyt-dependent replication in fibroblasts 
(41). Viral DNA is replicated via a rolling circle mechanism that generates concatemeric 
HCMV genomes. Concurrent with viral DNA replication is the expression of late genes. 
HCMV assembly and egress. The production of late proteins leads to procapsid 
assembly. These preformed capsids recognize and target the concatemeric viral DNA 
for encapsidation. Cleavage of the concatemer packages a single HCMV genome per 
capsid. The formation of the nucleocapsid is followed by an envelopment and de-
envelopment process to exit the nucleus (42). At the inner nuclear membrane, primary 
envelopment is triggered by the pUL97 mediated phosphorylation of the nuclear egress 
complex, subunits pUL50 and pUL53 (43). Subsequent de-envelopment occurs at the 
outer nuclear membrane and releases the nucleocapsid into the cytoplasm.  
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 While some tegument proteins are added to the nucleocapsid during nuclear 
egress, most are acquired in transit towards sites of secondary envelopment. 
Envelopment occurs at specialized, HCMV induced, cytoplasmic vesicles that contain 
markers for trans-Golgi, multi vesicular bodies, and endosomes (44-46). Budding of 
particles into these vesicles is followed by exocytosis, in which the mature virion is 
released from the cell. The cytoplasmic process of assembly, envelopment, and egress 
all occur inside the HCMV induced cytoplasmic virion assembly complex (cVAC).  
Cytoplasmic virion assembly complex. A hallmark of HCMV infection is 
nuclear and cytoplasmic enlargement or cytomegaly. Following 3 to 4 days post 
infection, the host cell nucleus takes on a kidney bean-like shape that partially wraps 
around a perinuclear structure termed the cVAC. This structure is the final site of virion 
maturation and necessary for efficient virion production. The formation of the cVAC 
involves the structural rearrangement of multiple cellular organelles. The interior 
compartment consists of a microtubule organizing center (MTOC) and EEA1 positive 
endosomes that are encircled by a ring of intertwined Golgi and trans-Golgi components 
(47). Microtubules emanating from the MTOC are thought to be responsible for the 
trafficking of virions through the cVAC (Fig. 2). Also, Rab GTPases and endosomal 
sorting complex required for transport (ESCRT) gather at the cVAC and are implicated 
in virion maturation; perturbing components of either pathway results in decreased viral 
titers (48-50). Rab proteins are master regulators that control the flow of membrane 
traffic and target viral proteins to their appropriate destination. ESCRT machinery 
perform membrane bending and scissioning events that may contribute to the budding 
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of nucleocapsids into endocytic vesicles (The role of ESCRT proteins is described 
further in the following section).  
In addition to cellular proteins, many viral tegument proteins and glycoproteins 
heavily localize to the cVAC for virion production (51, 52). A mature HCMV virion is 
composed of 70 different viral proteins with at least 32 being tegument proteins (53, 54). 
The process of virion assembly is incompletely understood, but requires, in part, 
tegument proteins pUL32 (pp150), pUL99 (pp28), pUL94, pUL71 and pUL103 (55-58).  
The second most abundant tegument protein, pUL32, serves a multifunctional 
role during infection. At early times, pUL32 localizes to the nucleus and is tightly bound 
to capsids (59-61). Initial studies with pUL32 antisense mRNA appeared to block the 
translocation of nucleocapsids to the cytoplasm, indicating a role in nuclear egress (62). 
In support of these knockdown studies, a UL32 deletion virus grown on complementing 
cells showed an accumulation of viral DNA in the cytoplasm, but few discernable 
nucleocapsids (63). In addition, mutagenizing pUL32 conserved region 1 (CR1) or CR2 
perturbed cVAC organization and virion maturation (63). This data indicates a dual role 
of pUL32 in stabilizing nucleocapsids and virion assembly.  
The UL99 protein is a highly conserved myristoylated and phosphorylated protein 
(64). The deletion or mislocalization of HCMV pUL99 (pp28) causes a defect in viral 
replication and irregular Golgi structures (56, 64, 65). Interesting, only the N-terminal 50 
amino acids that carry the multimerization, myristoylation, and pUL94 binding domain 
are necessary for virion production (64, 66). Disruption of a single cysteine residue at 
position 250 of pUL94, or the deletion of pUL99 residues 37-39 disrupts the pUL94-
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pUL99 interaction, which causes the dispersal of both proteins from the cVAC (55, 67). 
The proper localization of pUL94 and pUL99 is essential for virus production.  
Equally as important in the process of envelopment is pUL71. In the absence of 
pUL71, the cVAC contains abnormally large cytoplasmic inclusions labeled with LAMP1 
and CD63, markers for late endosomes and multivesicular bodies (68, 69). Virus 
particles located at these enlarged vesicles have delayed envelopment and thus 
impaired release. In transfection experiments, pUL71 binds to pUL103 with localization 
of pUL103 dependent on the pUL71interaction (70). Interestingly, a pUL103 deletion 
mutant also shows nucleocapsids suspended in the process of secondary envelopment 
and lower viral titers (58). These results suggest that pUL71 and pUL103 form a protein 
complex that functions during the final stages of virion maturation.  
The process of HCMV assembly and egress in the cVAC is highly complex and 
requires the concerted effort of viral and cellular proteins. A recent study shows viral 
proteins are able to subvert the antiviral function of interferon-induced transmembrane 
proteins (IFITMs) for cVAC formation and efficient virus production (71). Also, host 
proteins contribute to the proper localization of viral proteins, as in how Rab6 interacts 
with and traffics pUL32 to the cVAC during infection (50). The functions of these viral 
and cellular interactions are only beginning to be uncovered. Understanding the 
interplay between viral and cellular proteins in the cVAC will provide further insight to 
late stages of HCMV infection, as well as basic cell biology.  
ESCRT machinery. The process of subverting host cell machinery for virion 
production is a common theme among multiple viruses. Although not much is known 
about HCMV secondary envelopment, there is evidence that HCMV obtains its 
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envelope in endocytic compartments. (i) In HCMV infected cells incubated with 
horseradish peroxidase (HRP), virions and HRP were present in the same compartment 
(44). (ii) Purified infectious HCMV virions contain CD63, a multivesicular body marker 
(45). (iii) Dominant negative ESCRT components, CHMP1A and VPS4A reduce 
infectious yield (48). 
The formation of these endocytic vesicles is mediated by ESCRT machinery (Fig. 
3). The ESCRT pathway is initiated by ESCRT-0 subunits binding phosphatidylinositol 
3-phosphate, ubiquitinated proteins, and TSG101 of ESCRT-I. Sequential recruitment of 
ESCRT-I and ESCRT-II subunits concentrates ubiquitinated cargo to begin the 
membrane invagination process. Activation of the ESCRT-III complex completes the 
membrane scissioning and releases the newly formed vesicle. HCMV may use all or a 
combination of these players during secondary envelopment. 
In retroviruses, ESCRT machinery is recruited to sites of envelopment by signal 
motifs found on viral proteins. These signals are often the same or similar to those 
present on host cell proteins, and are termed “late” or “L” domains: P(T/S)AP, PPXY, 
and YPXnL. The P(T/S)AP late domain is used to recruit TSG101, and thus ESCRT-I, to 
sites of virion envelopment (72, 73). The PPXY motif binds WW domains of NEDD4 
family members that target specific proteins for ubiquitination (74). YPXnL late domains 
in retroviruses bind the V domain of ALG-2 interacting protein X (ALIX) to facilitate viral 
budding at the cell membrane (75-77). 
Although ESCRT machinery is critical for retrovirus budding, evidence of ESCRT 
involvement during HCMV envelopment is conflicting. siRNA knockdown of TSG101, 
ALIX, Vps4A and Vps4B in retinal pigment epithelial cells had either no effect or a slight 
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increase in HCMV virion production (78).  However, dominant negative versions of 
CHMP1A and VPS4A in human fibroblasts reduced infectious yields by 100-fold at 6 dpi 
indicating the necessity of ESCRT-III in virion production (48). In the same study, 
CHMP1A and Vps4A localized in or around the cVAC, but how these ESCRT-III 
components are recruited to sites of HCMV envelopment remains a mystery. Sequence 
analysis of HCMV tegument and glycoproteins revealed numerous late domains. One 
P(T/S)AP motif in pUL32, two PPXY motifs in gB and pUL48, and 7 HCMV proteins 
(including pUL103) with ALIX binding domains YPXnL. With this redundancy and 
multiple pathways leading to ESCRT-III recruitment (ESCRT-II, NEDD4, ALIX, or an 
unidentified viral protein), identification of functional late domains in HCMV may provide 
insight to the process of secondary envelopment.  
UL103. The HCMV UL103 gene encodes a tegument protein that is conserved 
among all human herpesviruses. Early work on the alphaherpesvirus homolog UL7 has 
shed light on the process of UL103 gene transcription. The UL7 gene is located on the 
unique long region of the genome and overlaps the upstream UL6 gene (homolog of 
HCMV UL104) at its 5’ end. Analysis of the UL7 and UL6 transcript reveals a shared 
poly A tail with both genes being transcribed simultaneously in herpes simplex virus 1 
(HSV-1) and psuedorabies virus 1 (PrV-1) (79, 80). The UL6 gene product is essential 
in forming the entry portal for packaging viral DNA in preformed capsids (81), while the 
UL7 gene is a nonessential structural protein with late transcription kinetics (79, 80, 82).   
The HCMV UL103 gene is similar to its alphaherpesvirus counterpart (UL7) in a 
variety of ways. (i) The UL103 gene shares 53 base pairs with the neighboring UL104 
gene, indicating cotranscription.  (ii) Expression of UL103 is regulated as a late gene 
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with the protein incorporated into virions ((54, 83)). (iii) Disruption or deletion of the 
UL103 ORF causes smaller plaque size, decreased viral titers, and defects in virion 
release (58, 82, 84-87). (iv) pUL103 and the HSV-1 homolog accumulate in the 
cytoplasm at late times post infection and colocalize with cytoplasmic membranes (58, 
88).  (v) The localization of pUL103 is dependent on its interaction with pUL71, which is 
also evident in the HSV-1 homologs pUL7 and pUL51 (70, 88). However, some 
properties of pUL103 are HCMV specific. For instance, HCMV produces sacs of 
enveloped tegument proteins called dense bodies during infection. The formation of 
dense bodies is independent of virion assembly, but the release of both particles is 
controlled by pUL103 (58). The properties of the highly conserved HCMV pUL103 have 
been explored extensively, yet the function of pUL103 during infection has yet to be 
elucidated.  
Insight to the possible functions of pUL103 can be gathered from previous 
studies on pUL7. For instance, the UL7 protein of HSV-2 appears in the nucleus and is 
weakly associated with A, B, and C capsids (89). Although HCMV pUL103 has not been 
identified as nuclear, it does contain a conserved G-F-x(8)-E-D-x-V-x(12)-R domain with 
similarity to DNA topoisomerase III of fission yeast, hinting to a possible role in 
packaging or DNA transcription. Also, co-immunoprecipitation of HSV-1 pUL7 pulled 
down cellular mitochondrial proteins ANT2 and ANT4 (82). The biological significance of 
these interactions was not pursued, but could be involved in regulating mitochondrial 
function to facilitate a productive infection.  
This work. Currently, there are only four drugs approved for HCMV treatment, 
but all target steps of DNA replication. Because of this, resistance to these types of 
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drugs is increasing. An alternative approach is to prevent cVAC assembly, and thus 
inhibit viral production. However, the viral proteins involved in cVAC formation have yet 
to be characterized.  
The focus of this work was to identify individual viral proteins that control cVAC 
biogenesis. The formation of the cVAC follows viral DNA synthesis, which implies a 
connection to late genes. Although this does not exclude immediate early and early 
gene involvement, it provides an initial starting point for viral genes to pursue. Also, a 
fully formed cVAC is critical for efficient virus production, so we chose to focus on late 
genes that display a growth defect when the ORF is disrupted. This led to the screening 
of 26 genes, from which three viral proteins (pUL48, pUL94, and pUL103) were 
identified as important for cVAC biogenesis. These three viral proteins as well as their 
interacting partners, whether they are viral or cellular proteins, can provide potential 
targets for developing anti-viral drugs. 
To further understand the functions of pUL103, we conducted a dual method 
approach of affinity purification followed by mass spectrometry to elucidate pUL103 
binding partners. By using two different methods and enriching for interactions identified 
by both, we were able to reduce the amount of false positives while also improving the 
likelihood of a true interaction. We identified and verified pUL103 interactions with 
multiple nuclear viral proteins (IE2, pUL34, and pUL44), an antiviral (IFI16) and ESCRT 
associated protein (ALIX). These interaction partners revealed a nuclear association of 
pUL103, as well as possible functions in the antiviral response and ESCRT machinery 
recruitment, suggesting a multifaceted role of pUL103 during HCMV infection.  
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Figure 1. Herpesvirus virion structure 
 
Used with permission from http://www.twiv.tv/virus-structure/  
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Figure 2. Schematic representation of the cVAC and proposed path of virion egress  
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Figure 3. Formation of intraluminal vesicles by ESCRT machinery; the proposed 
pathway for HCMV virion envelopment 
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CHAPTER TWO 
VERIFYING THE ROLES OF pUL48 AND pUL103 IN CVAV BIOGENESIS  
This chapter is written as published in the Journal of Virology, August 2014. 
Subhendu Das PhD conducted the siRNA screen to identify viral candidates involved in 
assembly complex biogenesis (figures 3-5). I constructed and characterized two 
recombinant viruses to verify the siRNA screen results (figures 6-13).  
Introduction 
 Herpesvirus virion assembly is a complex process (reviewed in (90, 91)).  A 
portion takes place in the nucleus, which is the site of viral DNA replication, formation of 
and filling the nucleocapsid with viral DNA, and acquisition of the initial tegument layer.  
The major pathway of virion maturation involves the nascent capsid budding through the 
inner nuclear membrane into the lumen of the nuclear membrane, thus acquiring the 
primary envelope.  Subsequently, the virion “infects” the cytoplasm through the outer 
nuclear membrane, leading to loss of the primary envelope.  Tegument components are 
added during movement through the cytoplasm to a vesicle into which the particle buds, 
acquiring its mature envelope.  The vesicle housing the virion is transported to the cell 
surface where the virion is released in an exocytic process. 
 Human cytomegalovirus (HCMV) induces cytopathic effects that include 
cytoplasmic and nuclear enlargement, and development of characteristic cytomegalic 
nuclear and cytoplasmic inclusions (reviewed in (92)).  The large cytoplasmic inclusion 
corresponds to the cytoplasmic virion assembly complex (cVAC) (51).  cVAC are large 
cylindrical structures that are present one per infected cell, even in multinucleate 
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syncytia.  Nuclei take on a kidney-like (reniform) shape as they bend partially around 
the cVAC (93).  Electron microscopic evidence indicates that the cVAC is the site of 
final tegumentation and envelope acquisition (44, 94, 95).  Viral tegument proteins, 
envelope proteins, and some non-structural proteins localize to the cVAC, and 
cytoskeletal filaments appear to radiate from a microtubule organizing center in the 
cVAC (46, 51, 96, 97).  The cVAC is relatively devoid of endoplasmic reticulum (ER) 
markers.  The ER-to-Golgi intermediate compartment (ERGIC), Golgi apparatus, and 
trans-Golgi network (TGN) form a cylindrical ring that outlines the cVAC (47, 51, 96). 
Tooze et al. (44) treated cells with soluble horseradish peroxidase, which is taken 
up by recycling endosomes, and found its reaction product of oxidized diaminobenzidine 
in cytoplasmic vesicles that contained what appeared to be tegumented and enveloped 
HCMV virions, providing direct evidence that the virion exit vesicle is related to recycling 
endosomes.  Consistent with this, we and others found that molecular markers of 
recycling endosomes (early endosome antigen 1 (EEA1) and Rab11) stain vesicles that 
cluster at the center of the cVAC (45, 47, 58, 96, 98).  Exactly how virions mature in the 
cVAC remains a mystery, and it has not been demonstrated whether a fully formed 
cVAC is necessary for efficient virion production.  Although structures morphologically 
similar to the HCMV cVAC have not been described for other herpesviruses, a recent 
study found that herpes simplex virus 1 virions acquire their envelope at tubular 
structures that share many properties with recycling endosomes (99). 
Although the full set of viral regulators of cVAC biogenesis has not been 
identified, some things are known: (i) cVAC do not form in the absence of viral DNA 
synthesis ((97) and our unpublished observations), indicating that its formation is 
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dependent on expression of one or more viral late genes; gene(s) from an earlier kinetic 
class may also be involved. (ii) Treatment of cells with nocodazole, which 
depolymerizes microtubules, leads to rapidly reversible cVAC disruption (100).  While 
microtubules are important (even essential) components of the cVAC, they are not likely 
to be regulators of cVAC biogenesis. (iii) The kinase activity of pUL97 is required for 
formation of perinuclear complexes that correspond to cVAC and for efficient production 
of infectious virions, but UL97 activity alone is insufficient for cVAC development (97, 
101, 102). (iv) Although not examined in detail, images in papers describing some 
HCMV mutants that have defects at late stages of virion assembly are consistent with at 
least some features of cVAC-like structures forming in the absence of UL32, UL91, 
UL96, UL99 (56, 57, 69, 103). (v) In contrast, insertion of a stop codon into the UL103 
open reading frame resulted in the absence of well-formed Golgi rings, but the recycling 
endosomal compartment was not studied (58).  In addition, in cells infected with a 
pUL71-deficient virus, viral proteins that normally associate with the cVAC are 
mislocalized (69). (vi) cVAC form in cells infected with highly passaged laboratory 
strains of HCMV that lack some genes present in wild type viruses (preceding 
references), as well as after infection with a low passage virus that encodes a nearly 
complete complement of HCMV genes (104).  Interestingly, an HCMV locus spanning 
UL133 to UL138 is required for cVAC development in human microvascular endothelial 
cells, but not in embryonic lung fibroblasts (104), indicating that cell-specific viral factors 
can be involved. (vii) In addition to protein regulators of cVAC biogenesis, HCMV 
microRNAs miR UL112-1, US5-1, and US5-2 target mRNAs of several host proteins 
involved in regulation of the cellular secretory apparatus (105).  A recombinant virus that 
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does not express these miRNAs did not induce formation of cVAC and produced 
significantly fewer infectious virions.  Ectopic expression of these microRNAs had some 
effects on Golgi structures, but full cVAC did not form. 
In prior studies we described the three dimensional structure of the cVAC, and 
the extensive remodeling of the cytoplasm and shifts in organelle identity that occur 
during cVAC development (98).   The objective of this work was to identify HCMV 
protein-coding genes that regulate cVAC biogenesis.  Using siRNAs that target a set of 
26 candidates, we identified three HCMV genes (UL48, UL94, and UL103) whose 
absence results in abrogation of cVAC development, without affecting expression of 
other viral genes.  Our results expand the set of functions assigned to HCMV genes, 
and will enable identification of the network of interactions between HCMV and the host 
cell secretory apparatus, provide new information about the process of virion assembly, 
and define new targets for development of novel antivirals. 
21 
 
 
 
Materials and Methods 
Cells and virus.  HCMV (AD169) (American Type Culture Collection, Manassas, 
VA) was grown in low passage human foreskin fibroblasts (HFF) in complete 
Dulbecco’s modified Eagle (DMEM) medium plus sodium pyruvate and MEM 
nonessential amino acids (Invitrogen, Carlsbad, CA), GlutaMAX (Invitrogen), and 5% 
FBS (HyClone, Logan, UT).  Virus was titrated by plaque assay on low passage diploid 
human foreskin fibroblasts.  For growth curves, supernatant virus was collected, 
purified, and stored at -80°C.  The siRNA experiments reported here were performed in 
low-passage human lung fibroblasts (HLF) (a gift from John Stewart, Centers for 
Disease Control and Prevention, Atlanta, GA) that were propagated in the medium 
described above but with 10% FBS and penicillin and streptomycin.  Antibiotics were 
omitted during experiments. 
siRNA screening and immunofluorescence assay.  Cocktails of four siRNAs 
that specifically target each candidate HCMV regulator of cVAC biogenesis were 
designed and synthesized by Dharmacon Inc. (Lafayette, CO).  For the transfection 
experiments, 2 x 104 HLF cells per well were seeded onto 0.2% gelatin coated 8-well 
glass chamber slides (LabTek, Nunc, Rochester, NY; catalog number 177402) for 1 h at 
37°C.  The following day, cells were transfected with 50 pmol SMARTPOOL siRNA 
using Lipofectamine 2000; 6 h after transfection, cells were infected at a multiplicity of 
infection (MOI) of 0.2 in DMEM containing 5% fetal bovine serum.  As previously 
described (16), after 120 h, cells were washed with PBS, fixed with 4% 
paraformaldehyde in PBS (lacking Ca2+ and Mg2+) at pH 7.4, and then autofluorescence 
was quenched by incubation for 15 min in 50 mM ammonium chloride.  Cells were 
subsequently permeabilized and then successively incubated with the primary 
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antibodies (described in Table 1) and fluorescent tagged secondary antibodies (Alexa 
Fluor 488- conjugated goat anti-mouse IgG and Alexa Fluor 568-conjugated goat anti-
rabbit IgG both from Molecular Probes, Carlsbad, CA).  Mounting was done with 
Vectashield containing DAPI (4’, 6-diamidino-2-phenylindole) (Vector Laboratories Inc., 
CA).  Imaging was done on a Leica TCS SP5 laser scanning confocal microscope.   
Construction of recombinant viruses.   Recombinant HCMV viruses were 
generated by recombineering using the AD169 bacterial artificial chromosome, pAD/Cre 
in SW105 (gift from Donald L. Court, National Cancer Institute), an E. coli strain which 
contain a temperature sensitive recombinase gene and an arabinose inducible Flp gene 
(106, 107).  pAD/Cre contains the AD169 genome flanked by loxP sites that excise the 
bacterial component of the BAC upon transfection into mammalian cells.  Due to 
overlapping adjacent coding regions at the 5’ end of the UL48 and UL103 genes, the 
FKBP segment (108), was inserted at the 3’ end of the target genes.  Selective markers 
(galK and kanamycin) flanked by FKBP and FRT sequences were PCR amplified from 
pYD-C630 (provided by Dong Yu, Washington University) (109).  Primers for 
recombineering are listed in Table 2.  Positive selection of the FKBP GalK/kanamycin 
cassette was carried out on kanamycin Luria broth agar plates. Selection markers were 
removed by inducing the SW105 Flp recombinase, leaving UL48-FKBP or UL103-FKBP 
with an FRT site in frame at the C-terminus.  Removal of the GalK selection marker was 
verified by selection on galactose indicator plates.  Galactose negative colonies were 
picked, and verified by restriction enzyme analysis, PCR, and DNA sequencing.  To 
create UL103-FKBP-V5, the GalK/kanamycin cassette was replaced by amplifying and 
recombining the V5 tag.  Negative selection of the GalK was performed on M63 minimal 
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media plates supplemented with glycerol, D-biotin, L-leucine, 2-deoxygalactose, and 
chloramphenicol.  Loss of the GalK was verified as described above.  All viruses were 
reconstituted by using Lipofectamine 2000 to transfect HFFs with 8-10 µg of BAC DNA, 
followed by propagation in the presence of 1 µM Shield-1 (Cat no. CIP-AS1, 
Cheminpharma, Farmington, CT), which was replaced every 48 hours to maintain its 
activity.  Virus was collected when the monolayer showed >80% cytopathic effect.  Virus 
stocks were grown by infecting HFFs at a multiplicity of infection of 0.01 in the presence 
of 2 µM Shield-1; extracellular virions were partially purified by centrifugation through a 
20% sucrose cushion. 
Immunoblots.  HFFs were grown to confluence in T25 flasks and mock infected 
or infected at an MOI of 0.1.  At 5 dpi, cells were washed with PBS and then lysed with 
RIPA buffer (0.1 M Hepes pH 7.4, 0.1% sodium deoxycholate, 150 mM NaCl, 1% NP-
40, 0.1% SDS, and Roche protease inhibitor).  Protein concentrations were determined 
by BCA assay (Pierce, Rockford, IL).  Equal amounts of protein solubilized in 2X SDS 
Laemmli buffer with 2-mercaptoethanol were separated in 10% SDS polyacrylamide 
gels, transferred to nitrocellulose membranes (Whatman, Florham Park, NJ), probed 
with primary antibodies, and then reacted with HRP-conjugated goat anti-rabbit/mouse 
IgG secondary antibodies (Thermo Scientific, Rockford, IL).  Reactions were detected 
with the Supersignal West Pico Chemiluminescent substrate (Thermo Scientific, 
Rockford, IL) on autoradiography film (GE Healthcare, Pittsburgh, PA).  Antibodies are 
listed in Table 1. 
Electron microscopy.  Transmission electron microscopy was done by Dr. 
Hong Yi at the Robert P. Apkarian Integrated Electron Microscopy Core Facility of 
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Emory University, Atlanta, GA, using methods developed Dr. Yi in collaboration with 
Ahlqvist, Tandon, and Mocarski (58, 103).  Briefly, HFF were infected in the presence 
and absence of Shield-1 with the parental (pAD/Cre) or the UL103-FKBP virus at MOI = 
0.3.  At 120 hpi cells were washed with fixative (2.5% glutaraldehyde in 0.1 M sodium 
phosphate buffer (pH 7.4)), and then incubated in fixative for 20 min at room 
temperature. After overnight storage in fixative at 4°C, cells were shipped submerged in 
the fixative.  Cells were postfixed in the same buffer with 1% osmium tetroxide, 
dehydrated through a graded series of ethanol, and then embedded in an epoxy resin.  
Cell culture dishes were broken, and ultrathin sections were then cut and 
counterstained with uranyl acetate and lead citrate.  The Hitachi H-7500 was operated 
at 75 kV, and images were captured using a Gatan BioScan (Pleasanton, CA) charge-
coupled device camera. 
25 
 
 
 
Results 
Screening strategy to identify viral genes required for cVAC development.  
Based on the requirement for viral DNA synthesis for cVAC biogenesis, and the 
hypothesized importance of the cVAC in virion maturation, we identified 26 HCMV 
genes as possible regulators of cVAC biogenesis (Table 3) and used siRNAs to 
individually silence them during infection.  Effects on cVAC development were 
visualized by confocal microscopic analysis of markers that are collectively diagnostic 
for cVAC structure. 
The synthetic siRNAs used were mixtures of 4 siRNA duplexes, each of which 
independently targets the transcript of interest (Dharmacon SMARTpools).  Use of such 
pools instead of single siRNAs increases specificity by reducing the input concentration 
of individual siRNAs, thereby reducing off target effects.  Pools also increase the 
likelihood of successful silencing because four regions of the target gene are targeted at 
once.   Although antibodies are not available against most of the proteins whose 
expression we targeted, similarly designed siRNA pools that target HCMV proteins for 
which we have antibodies (IE2, MDBP, UL99, US17, and US18) delivered satisfactory 
results for every target tested ((110) and data not shown).  Nonetheless, negative 
effects of individual siRNA pools should not be taken as proof that the targeted gene 
has no effect on cVAC biogenesis. 
Screening experiments were done in 8-well glass chamber slides.  Human lung 
fibroblast (HLF) cells were transfected with the siRNAs 6 to 8 hr prior to infection with 
fully infectious HCMV (AD169).  As a reminder, siRNAs do not affect input protein 
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levels, but reduce levels of proteins expressed from genes transcribed during infection.  
At 120 hpi, cells were fixed and stained with the indicated antibodies. 
The antibodies used in our antibody cocktails give reliable and distinct staining 
patterns that are collectively diagnostic for cells being infected, expression of viral late 
genes, and formation of the cVAC (Fig. 4A; Table 4).  To validate the screening 
strategy, we used 100 µg/ml phosphonoacetic acid (PAA)-treated, HCMV-infected cells 
as a prototype of a gene silencing experiment. PAA inhibits viral DNA synthesis, 
consequently inhibiting cVAC biogenesis in HCMV infected cells.  As shown in Fig. 4B, 
in the presence of PAA, markers of the secretory apparatus in infected cells resembles  
those in uninfected cells. 
HCMV genes involved in cVAC biogenesis identified through the use of 
siRNAs.  Over 400 confocal images were analyzed as part of the screening process.  
Phenotypes observed after siRNA treatment included: no effect, toxic effects, absence 
of HCMV late gene expression, and inhibition of cVAC formation in cells where HCMV 
late genes are expressed.   Candidate regulators of cVAC biogenesis were defined as 
genes whose silencing did not affect HCMV gene expression but prevented formation of 
perinuclear Golgi rings surrounding concentrations of EEA1 staining, with emphasis on 
the EEA1 patterns. 
The results from our siRNA screen of 26 HCMV genes are summarized in Table 
5.  Some siRNAs had no visible effects on infected cells, while others caused extensive 
cytopathic effects, including blobs of dead cells, small nuclei, and irregularly shaped 
nuclei.  These diverse effects might be products of silencing viral genes that are 
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involved in regulating any of a variety of cellular processes, including protein secretory 
pathways, cellular metabolism, and anti-apoptotic activity. 
The three genes whose siRNAs resulted in the most significant and specific 
effects on cVAC development were UL48, UL94, and UL103.  In the presence of 
siRNAs against each of these genes, HCMV late genes were expressed, Golgi rings 
formed in few cells, and the early/recycling endosome machinery was dispersed, nearly 
absent, or otherwise disrupted (Fig. 5).  An important pathognomonic change 
associated with HCMV infected cells is development of enlarged nuclei that take on a 
reniform (kidney bean) shape; these changes are important during cVAC biogenesis 
(93).  Knockdown of all  three of the candidate cVAC biogenesis regulators (UL48, 
UL94, and UL103) resulted in significantly lower ratios of reniform to oval nuclei 
compared to untreated cells and cells treated with siRNAs against several other genes 
targeted in our screening (Fig. 6).  Some of the known properties of these candidate 
regulators are listed in Table 6. 
Use of regulated protein destabilization to verify the siRNA screening 
results.  To independently confirm the siRNA results, and to address specificity issues 
that might arise from overlapping transcripts previously described across UL48, UL94 
and UL103, we employed regulated FKBP-mediated protein destabilization of the 
proteins of interest (Fig. 7; (108)).  The FKBP moiety targets tagged proteins for rapid 
proteasomal degradation, and the stability of the proteins tagged with FKBP domains 
can be regulated by the concentration of Shield-1.  Due to coding region overlaps 
between each of the genes of interest and their upstream neighbor, the FKBP domain 
was fused in place of the stop codon at the C-terminus of each protein.  Recombinant 
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BACs were transfected into two cultures that were grown in the presence and absence 
of Shield-1.  The UL48 recombinant (UL48-FKBP) produced many fewer and much 
smaller plaques in the absence of Shield-1 (data not shown), providing a preliminary 
indication that the FKBP domain was having the desired effect.  As expected because 
UL103 deletion mutants are viable, the UL103 recombinants (UL103-FKBP and UL103-
FKBP-V5) produced infectious virions under both conditions.  We were not able to 
reconstitute a viable virus from a UL94-FKBP BAC. 
 We used immunofluorescence and immunoblots to verify our ability to regulate 
the stability of the proteins of interest.  pUL48 was detected using  an antibody against 
its N-terminus (kindly provided by Wade Gibson) (111).  Because highly specific 
antibodies are not available for detection of pUL103, a 14 amino acid V5 epitope tag 
was added to the C-terminus of UL103-FKBP (UL103-FKBP-V5).  For UL48-FKBP, 
addition of Shield-1 markedly increased the amount of pUL48 detected by 
immunofluorescence (Fig. 8A) (6.2-fold per cell based on 3D quantification of at least 8 
cells for each condition). By densitometry, there was a 3.1-fold increase of pUL48 in the 
presence of Shield-1 (Fig. 8C).  The amount of pUL48 expressed by the UL48-FKBP 
virus in the presence of Shield-1 is less than that produced by the parental virus.  When 
UL103-FKBP-V5 is grown in the absence of Shield-1, the UL103-FKBP-V5 protein is 
very faint and dispersed when visualized by immunofluorescence, with marked 
increases when Shield-1 is present (3.1-fold by IFA and 4.2-fold in immunoblots) (Fig. 
8B and 8D).   Thus, addition of the FKBP destabilization domain to pUL48 and pUL103 
enables regulation of their stability.  Immunoblots showed little difference in expression 
of virus genes from all three lytic classes in the presence or absence of pUL48 or 
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pUL103 stabilization (Fig. 9), and only modest differences were seen in intracellular 
DNA levels by quantitative PCR (data not shown). 
Having verified the intended effects of Shield-1 on viral proteins, the effect of 
regulated protein degradation on cVAC structure was analyzed by staining viral and 
cellular markers of the cVAC in the presence or absence of Shield-1 (Figs. 10 and 11).  
Shield-1 had no significant effect on cVAC development for the parental virus (Fig. 11).  
pUL48 destabilization in absence of Shield-1 led to dispersal of early/recycling 
endosomes, and absence of the characteristic Golgi ring, as was seen in the siRNA 
experiments.  cVAC biogenesis appeared to be normal in most cells in which pUL48 
was stabilized with Shield-1.  Similar results were seen for UL103-FKBP.  In an anaylsis 
of over 800 cells, cVAC disruption in the absence of Shield-1 was statistically significant 
(p<0.0001) (Fig. 11).  Thus, in accordance with the siRNA screen, destabilization of 
pUL48 and pUL103 disrupted cVAC formation, verifying their importance in cVAC 
biogenesis. 
Growth properties of recombinant viruses in the presence and absence of 
Shield-1.  The siRNA and protein stability experiments described above were done at 
low multiplicity and employed cVAC morphology endpoints visible in infected cells at 4 
or 5 dpi.  To determine whether destabilization of pUL48 or pUL103 influences virus 
growth, we compared the growth of three recombinant viruses (UL48-FKBP, UL103-
FKBP, and UL103-FKBP-V5) with their parent (pAD/Cre).  Time courses of production 
of extracellular infectious virions were examined at low and high MOI (multi- and single-
step growth curves, respectively).  At low MOI, not all cells are infected at the time of 
inoculation.  Thus, multiple rounds of replication can take place, enabling examination of 
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virus dissemination in terms of production of secondary plaques, features such as 
plaque size, and dependence on conditions created when cells are not exposed to large 
numbers of viral particles, many of which are not independently infectious (e.g., HCMV 
dense bodies and non-infectious enveloped particles).  At high MOI, essentially every 
cell in the culture is infected simultaneously, and cells are also exposed to large 
numbers of bioactive non-infectious particles.  Such synchronized infections provide 
information about how much infectious virus is produced during a single round of 
replication.  
 For UL48-FKBP, the single- and multi-step growth infections were done in the 
presence or absence of Shield-1 (Fig. 12A).  Progeny extracellular virions were titered 
in triplicate in the presence of the drug.  Somewhat unexpectedly, the single-step 
growth curves for UL48-FKBP showed one-log growth defects starting at 3 dpi, 
regardless of whether Shield-1 was present or absent; the defect persisted over the 6 
day experiment.   Likewise, in the multi-step analysis, UL48-FKBP growth was similar in 
the presence and absence of Shield-1; mutant infectious progeny were first detected at 
6 dpi, and infectious yields lagged by ~3 logs until 15 dpi, when they were about 1 log 
lower than for the parental virus.  Inefficient growth of the UL48-FKBP virus might be 
attributable in part to the lower overall level of pUL48 expressed in the presence or 
absence of Shield-1 (Fig. 8C). 
The UL103-recombinant virus stocks were also grown with Shield-1.  In single- 
and multi-step analyses, the presence of Shield-1 had little effect on the yield of 
extracellular infectious virus (Fig. 12B). Titers were similar when measured in the 
presence or absence of Shield-1 (data not shown), the only difference being plaque 
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sizes (see below).  In the single-step experiment in the absence of Shield-1, the UL103-
FKBP recombinant virus produced infectious extracellular virus at rates similar to its 
parent at most time points, with a <10- fold difference at 3 dpi.  In contrast, Ahlqvist and 
Mocarski found up to a 50-fold decrease in extracellular infectious titer with a Towne-
BAC mutant that does not express pUL103 (15).  These results suggest that at high 
multiplicities of infection, there is some compensation for the absence of pUL103 by a 
complementary function likely provided by another viral protein.  In multi-step 
experiments, the UL103-FKBP and UL103-FKBP-V5 viruses lagged in extracellular 
virus production by 2 to 3 logs at 3 and 6 dpi, ultimately reaching parental titers 9 to 15 
dpi.  In marked contrast, a pUL103-null virus produced ~3000-fold less extracellular 
infectious titer (15).  This indicates that even small amounts of pUL103 expressed by 
the UL103-FKBP virus are sufficient to support near parental growth.  The latter point is 
supported by our observations that (i) at low multiplicities, the small amount of pUL103 
produced by our FKBP-tagged viruses is sufficient to rescue about two logs of the early 
(3 to 6 dpi) growth defect seen in the absence of pUL103, with the growth defect being 
overcome 9 to 15 dpi, and (ii) growth of these viruses at moi = 0.1 was similar to that in 
the single-step analysis (data not shown); the growth defect was only seen at low moi. 
In other growth experiments with FKBP-tagged UL48 and UL103 viruses, we saw 
little effect of Shield-1 over concentrations ranging from 0 to 4 μM/ml (data not shown).  
These results suggest that although the FKBP domain enables regulated stability of 
pUL48 and pUL103, as well as regulation of their activity in cVAC biogenesis, for both 
proteins the FKBP tag inhibits some aspect of production or egress of infectious virions.  
As mentioned, for pUL103, this effect was largely overcome by 9 to 15 dpi. 
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Ahlqvist and Mocarski found that viruses deficient in expression of pUL103 
produce significantly smaller plaques (58).  Consistent with this, we found that Shield-1 
could rescue the small plaque phenotype of the UL103-FKBP virus (Fig. 13).  Thus, in 
addition to its roles in cVAC biogenesis and virion maturation or egress, pUL103 has a 
role in cell-to-cell spread of infection.  In contrast, the UL48 recombinant virus produced 
small plaques in the presence and absence of Shield-1 (data not shown). 
In ultrastructural analyses, in the absence of Shield-1, cytoplasmic UL103-FKBP 
virions were more likely to have aberrant appearances, including frequent appearance 
of virions that appeared to be arrested or greatly slowed down in the midst of acquiring 
their envelope (Fig. 14). 
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Discussion 
Little is known of the effectors of HCMV cVAC biogenesis, a biological process 
that is distinct from cVAC operation.  Structures architecturally similar to the cVAC 
(Golgi rings surrounding a cluster of early/recycling endosomes, and spatial segregation 
of the early/recycling and late endosomal systems) have been identified in uninfected 
cells (112-114).  cVAC biogenesis may thus be a product of the virus activating, and 
possibly modifying, a previously programmed biological process.  Like other biological 
pathways regulated by HCMV (e.g., immune responses, apoptosis, and the 
AKT/PI3K/mTOR pathway) (115, 116), we anticipate multiple points of control of the 
process by the virus, including the recently described role of HCMV microRNAs in cVAC 
biogenesis (105).  In addition to the virologic lessons, elucidation of this pathway and its 
points of control will be informative with respect to important areas of cell biology. 
 Using siRNAs, we screened HCMV early/late and late genes known to be 
important for efficient lytic replication for their activity in cVAC biogenesis.  Of the 26 
genes tested, only inhibition of expression of UL48, UL94, and UL103 specifically 
prevented cVAC biogenesis: Golgi rings did not form and the early/recycling endosome 
complex was disrupted, in the context of infections that had proceeded to at least late 
gene expression. 
The genes for all three candidate cVAC regulators have coding regions that 
overlap with coding regions of their neighboring genes, and polycistronic transcripts 
span each gene locus (Fig. 7).  To address the possibility that the siRNA effects were 
due to silencing of overlapping transcripts, we tagged each candidate protein with a 
regulatable post-translational destabilization domain.  Although we were not able to 
reconstitute a viable virus from a BAC containing a tagged version of UL94, viable 
34 
 
 
 
recombinants were reconstituted for UL48 and UL103, and we demonstrated regulated 
stability of the proteins of interest.  HCMV IE, early, and late genes were expressed at 
near-parental levels regardless of pUL48 or pUL103 degradation.  When pUL48 or 
pUL103 were destabilized, cVAC biogenesis was impaired, in a manner similar to what 
was seen following siRNA treatment, thus confirming the siRNA result and verifying its 
specificity for these genes.   
Our siRNA results are consistent with prior reports that HCMV UL94 and UL103 
are important for late stages of HCMV virion assembly and egress (55, 58).  From the 
UL103-FKBP virus we learned that the pUL103 domain necessary for cVAC biogenesis 
is distinct from at least two other functional domains.  Specifically, defects in plaque size 
(Fig. 13) and secondary envelopment (Fig. 14) were able to be rescued by Shield-1, 
and the C-terminal FKBP tag appears to alter production of extracellular infectious virus 
in a manner that is impervious to, and possibly worsened by stabilization of the tagged 
protein with Shield-1 (Fig. 12B).  We also provide new evidence that HCMV pUL48 is 
important for production of infectious extracellular virus, perhaps analogous to the role 
of its herpes simplex virus 1 homolog in production of non-infectious light bodies (117).  
Similar to the behavior of the UL103-FKBP virus, this defect in the UL48-FKBP virus 
was not rescued by Shield-1, in contrast to the cVAC biogenesis activity.  More detailed 
studies of the roles of these proteins in cVAC biogenesis will require generation of 
reagents that do not include tags that interfere with functions of the proteins of interest. 
The three HCMV proteins whose silencing prevented cVAC formation are virion 
tegument proteins that are conserved across the Herpesviridae (Table 6).  It has been 
suggested that HCMV UL103 and its orthologs in other herpesviruses play related roles 
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in the final stages of virion assembly (58).  While structures analogous to the HCMV 
cVAC have not been identified for other herpesviruses, is possible that these conserved 
proteins are all involved in remodeling infected cells into virus production factories.   
It is clear that multiple viral and cellular gene products play important roles in 
cVAC biogenesis.  We hypothesize that collective interactions of these factors, with 
each other and with other viral and cellular proteins, establish an environment 
conducive to cVAC development.  The viral proteins identified here as regulators of 
cVAC biogenesis will be useful probes for identifying and understanding the network of 
viral and cellular genes involved in cVAC biogenesis and virion maturation, a necessary 
prelude to developing novel antivirals that block the process. 
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TABLE 1.  Antibodies used in IFA and immunoblot assays 
 
Antibody target Host/isotype, clone Source, catalog no. 
Epitope tag 
V5 (14 amino acids) Mouse monoclonal/IgG2aκ LifeTechnologies, R960-25 
Cellular 
GAPDH (36 kDa) Mouse monoclonal/IgG1, clone GA1R ThermoScientific, MA5-15738 
GM130 (130 kDa) Mouse monoclonal/IgG1(κ),clone 35/GM130 BD Biosciences, 610822 
EEA1 (180 kDa) Rabbit polyclonal Abcam, ab2900 
HCMV 
IE1 and IE2 (IE1, 72kDa; IE2, 
86kDa) 
Mouse monoclonal/ IgG1(k), clone CH160 Virusys, P1215 
IE2 (86kDa) Mouse monoclonal, clone 8B1.2 Chemicon (Millipore), MAB810 
pUL44 (CMV ICP36), 46 kDa Mouse monoclonal/ IgG1(k), clone 10D8 Virusys, CA006-100  
UL48 (N-terminal region) Rabbit polyclonal Wade Gibson (Johns Hopkins 
University) (118) 
pUL99 (pp28) Mouse monoclonal/IgG2A(k), 5C3  Virusys, CA004-100  
gB (55 kDa and 110 kDa) Mouse monoclonal/ IgG1(k), clone 2F12 Virusys, CA005-100  
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TABLE 3.  Targets for siRNA screening: HCMV Early-Late and Late genes essential or 
important for viral growth 
Function  Gene(s) 
Tegument  R:  UL97* 
   E:  UL32, UL48, UL82, UL94, UL99 
Glycoproteins E:  UL55, UL73, UL75, UL100, UL115 
Unknown  R:  UL21, UL29, UL30, UL69, UL103,  UL117 
   E:  UL34, UL49,  UL71*, UL76*, UL91, UL92, UL93, UL95, UL96 
R = reduced; viral growth reduced by at least 50-fold 
E = essential; no viral replication its absence 
Replication data are from (84) and (85), kinetic class assignments are from (83). 
*Kinetic class not assigned in (83). 
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TABLE 4.  Targets and purposes of antibody cocktails used in screening assays 
 
Antibodiesa  
Cocktail 
Mouse Monoclonals 
 
Rabbit Polyclonals 
 
Purposeb IE2 pUL99 EEA1 GM130  MannII US18 
A +     +  confirms infection and Golgi ring formation 
B  +    +  
confirms Golgi ring formation, and late 
gene expression and localization 
C   +   +  
confirms Golgi ring formation and EEA1 
relocalization 
D    +  +  confirms Golgi ring formation 
E +      + 
confirms infection, and late gene 
expression and localization 
F  +     + confirms late gene expression 
G   +    + 
confirms EEA1 relocalization, and late 
gene expression and localization 
H    +   + 
confirms Golgi ring formation, and late 
gene expression and localization 
a+, present in cocktail 
bIE2, pUL99 and US18 detect different stages of infection, GM130 and Mann II stain Golgi rings, and 
EEA1 localizes at the center of cVAC. 
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TABLE 5.  HCMV genes screened by siRNA: properties and silencing results 
Gene Gene propertiesa 
siRNA results Candid
ate 
cVAC 
regulat
orc 
Unusual cytopathic 
effectsb Late gene expression 
Effect on Golgi and EEA1 
markers 
UL21A Enhances replication Yes 
 
No change in expression 
of pUS18/gB 
Small effect on Golgi 
markers, but not on EEA1  
UL29 Unknown  Yes (Many nuclei are     
very small, blob of 
dead cells and empty 
patches) 
No change in the 
expression of pUS18 
and pUL99 
None 
 
 
UL30 Unknown; alters PML morphology Yes (Blob of dead cells  
and empty patches) 
No change in expression 
of pUS18/gB 
Small effect on Golgi 
markers, but not on EEA1  
UL32 Major tegument protein, binds to 
capsid 
Yes (Blob of dead cells  
and altered nuclear 
form) 
Reduced (Altered 
distribution of pUL99 
[mainly cytoplasmic]) 
None 
 
UL34 Represses US3 transcription; 
shuttles between nucleus and 
cytoplasm 
Yes Altered distributions of 
pUL18 and pUL99 
Golgi markers did not form 
good rings, but EEA1 was 
still in tight perinuclear 
cluster. 
 
UL48 Large tegument protein; ubiquitin-
specific protease (N-terminal 
region); involved in capsid 
transport 
Yes Higher proportion of 
pUS18 in non-cVAC 
cytoplasm; expression 
of pUL99 reduced 
Fuzzy and diffuse EEA1;  
altered localization of 
Golgi markers, and 
absence of Golgi rings; 
few conventional cVACs 
Yes 
UL49 Unknown Yes (Many small  
nuclei) 
No change in expression 
of pUS18, but gB was 
more diffuse 
Small effect on Golgi 
markers, but not on EEA1  
UL55 
(gB) 
 
Virion envelope glycoprotein, gB; 
involved in heparan sulfate 
mediated virion entry, and cell-to-
cell spread 
Yes 
 
Altered distribution of 
pUS18, and reduced gB 
expression 
Small effect on Golgi 
markers, but none on 
EEA1 
 
 
UL69 Tegument protein; multifunctional 
regulator; shuttles between 
nucleus and cytoplasm; inhibits 
pre-mRNA splicing; exports virus 
mRNA from nucleus 
Yes (Empty patches,  
irregular forms of 
nucleus   and 
sometimes stretched) 
Higher expression of 
pUS18 in non-cVAC 
cytoplasm;altered 
expression pattern of 
pUL99 
None 
 
UL71 Tegument protein; involved in 
virion morphogenesis 
Yes (Blobs of dead 
cells) 
Reduced; Altered 
distribution of pUL99 
None 
 
UL73 
(gN) 
 
Virion envelope glycoprotein, gN, 
complexed with envelope gM;  
supports virion morphogenesis 
Yes (Many small 
nuclei) 
 
Expression of pUS18  
reduced;altered 
distribution pattern of 
pUL99 
None 
 
 
UL75 
(gH) 
 
Virion envelope protein, gH; 
complexed with envelope gL; 
involved in cell entry, and cell-to-
cell spread 
Yes (Many small 
nuclei) 
 
Expression of pUS18  
reduced;altered 
distribution pattern of 
pUL99, mostly 
cytoplasmic 
Reduced expression of 
Golgi markers and EEA1 
but no changes in their 
arrangement 
 
UL76 Virion protein; affects translation 
of UL77 
Yes Small altered expression 
of pUS18 and pUL99 
Altered distribution of Golgi 
markers but not EEA1  
UL82 Tegument phosphoprotein pp71; 
upper matrix protein; involved in 
gene regulation  
Yes (Many small  
nuclei) 
No change in expression 
of US18, but reduced 
gB expression 
Altered and reduced 
expression of Golgi 
markers, but not on EEA1 
 
UL91 Unknown Yes (Many small  
nuclei) 
No change in expression 
of pUS18 and pUL99 
Altered distribution of Golgi 
markers but not EEA1  
UL92 Unknown; members of this family 
found in several herpesviruses, 
including EBV BDLF4, HCMV 
UL92, HHV8 ORF31 and HSV6 
U63 
Yes (Many nuclei are  
very small, blob of 
dead cells     and 
empty patches) 
Slightly altered expression 
of US18 and pUL99 
None 
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UL93 Capsid-associated; involved in 
DNA encapsidation and capsid 
transport 
Yes (Blob of dead cells  
and empty patches) 
Slight altered expression 
of    pUS18, but not in 
pUL99 
None 
 
UL94 Tegument protein; involved in 
virion secondary envelopment 
Yes 
 
No effect on pUL99 or 
pUS18 expression 
levels. 
Greatly reduced EEA1 
expression; partial effect 
on Golgi markers, forming 
small Golgi ring 
Yes 
UL95 Late gene activator; found in 
several herpesviruses, include 
EBV BGLF3 and other UL95 
proteins (e.g., HCMV UL95, HSV-
1 UL34, and HHV6 U67) 
Yes (Blob of dead cells  
and empty patches) 
Slightly altered expression 
of pUS18, but not 
pUL99 
Altered distribution of Golgi 
markers but not EEA1 
  
UL96 Tegument protein; stabilization of 
nucleocapsids during nucleo-
cytoplasmic translocation; 
possibly involved in virion 
morphogenesis 
Yes (Many blob of 
dead cells) 
Altered distribution; 
increased expression of 
pUL99 
None 
 
UL97 Tegument protein; virion 
serine/threonine protein kinase 
Yes Reduced None 
 
UL99 Myristylated tegument protein; 
involved in virion morphogenesis 
Yes Reduced None 
 
UL100 
(gM) 
Virion envelope glycoprotein, gM; 
8 transmembrane domains; 
complexed with envelope gN; 
involved in virion morphogenesis 
Yes (Blob of dead cells  
withnuclear debris, 
patches of empty 
spaces and many  
small nuclei)  
Slightly altered distribution 
of  pUS18 and pUL99 
Altered expression of Golgi 
markers, but not of EEA1 
  
UL103 Tegument protein; involved in 
virion and dense body egress; 
DNA encapsidation 
Yes (Big empty  
patches) 
US18 looks normal, but 
altered distribution of 
UL99 
Golgi markers and EEA1 
are greatly reduced; 
Altered distribution of  
Golgi markers 
Yes 
UL115 Virion glycoprotein gL; complexed 
with envelope gH; involved in cell 
entry andcell-to-cell spread 
Yes (Blobs of dead  
cells) 
Less abundant (late virion 
proteins/cVAC markers) 
Reduced EEA1 expression;  
little effect on Golgi 
markers; Golgi rings with 
EEA1 center still present 
 
UL117 Enhances replication 
compartment formation; impairs 
cellular DNA synthesis 
Yes (Many are very  
small and bright blue 
blobs [apoptotic 
debris?]) 
Expression of pUS18 
altered   fuzzier cVAC 
association;    altered 
distribution pattern of 
pUL99 in some cell 
Little effect on Golgi 
markers or EEA1 
 
a Gene function information is reviewed in (119).  
b In most instances, unusual cytopathic effects consisted of numerous blobs of dead cells and altered 
nuclear forms (smaller, elongated, or irregular shapes).   
c Candidate cVAC regulators are the genes we selected for further study; this does not preclude other 
genes being important in the process. 
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TABLE 6.  Properties of candidate regulators of HCMV cVAC biogenesisa 
HCMV 
gene 
Homologs 
 
Functions and properties of HCMV homolog 
Interacting viral 
partners 
(HCMV only) HSV γHV HHV6  
UL48 UL36 ORF64 U31  Essential 
Largest tegument protein 
Has deubiquitinating enzyme activity 
Role in intracellular capsid transport 
pUL45, pUL47, 
pUL50, pUL69, 
pUL88, pUL103, 
and pUL132  
UL94 UL16  ORF33 U65  Essential 
Tegument protein 
Binds single-stranded DNA 
Cytoplasmic egress 
pUS22, pUL72, 
pUL82, and pUL99 
UL103 UL7  ORF42 U75  Elimination of pUL103 expression reduces virus replication 
by 102 to >104-fold, and results in reduced plaque size. 
May have a role in viral replication  
Tegument protein 
Associated with the cVAC 
Virus particle and dense body egress 
pUL22A, pUL48N, 
and pUL103 
aInformation in this table is from the following references: (55, 58, 67, 84, 85, 120-123) 
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Figure 4.  Validation of siRNA screening system.  (A) Diagrammatic representation of 
cVAC staining pattern in the HCMV infected human lung fibroblasts, and the predicted 
outcomes following silencing of cVAC biogenesis regulators.  The illustrated patterns 
are representations of previously published data (47, 96, 98).  (B) Inhibition of cVAC 
biogenesis by PAA (Cat. no. P6909, Sigma-Aldrich, St. Louis, MO) treatment in HCMV 
infected fibroblasts; confocal images are shown alongside the predicted patterns. 
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Figure 5. siRNA-based identification of UL48, UL94, and UL103 as candidate 
regulators of cVAC biogenesis. Cells were treated with siRNA pools designed to 
target the indicated HCMV genes, stained with antibodies against the indicated cellular 
markers and then examined by confocal microscopy.  A subset of the results obtained 
using the full panel of markers illustrated in FIG. 3 is shown here.  The staining patterns 
for the full set of markers were consistent with UL48, UL94, and UL103 playing 
important roles in cVAC biogenesis. 
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Figure 6. Ratios of reniform and oval nuclei in HCMV infected cells after gene 
silencing.  HCMV infected cells with reniform or oval shaped nuclei were counted in 
cells with or without silencing of the indicated genes.  The significance of the differences 
were evaluated using the Chi Square test.  n, number of cells examined for each 
condition; p, level of significance. 
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Figure 7. Gene arrangements and transcripts in the vicinity of the candidate 
regulators of cVAC biogenesis.  5’ ends of mRNAs are indicated with balls, and 3’ 
polyadenylated regions with “An”.  Genetic recombineering methods described in 
Materials and Methods were used to introduce the FKBP degradation domain into our 
genes of interest.  All three genes overlap with neighboring genes at their 5' end. To 
avoid effects on overlapping coding regions at the N-termini of the three genes, the 
FKBP destabilization domain was added at the C-terminus of each gene.  UL48 maps: 
(124); UL94 maps: (125-127); PRV UL7 (HCMV UL103 homolog) map: (124) and 
HCMV UL103 (22).   
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Figure 8. Verification of regulated protein degradation. The UL48-FKBP and UL103- 
FKBP-V5 tagged proteins were analyzed by (A and B) confocal immunofluorescence 
microscopy, and (C and D) immunoblots in the presence and absence of Shield-1.  
HFFs were infected for 120h at a MOI of 0.1.  pUL48 was detected using an antibody 
against its N-terminus (C), and pUL103 was detected using an anti-V5 antibody (D).   
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Figure 9. Effect of protein destabilization on other HCMV proteins. Cells were 
infected (MOI = 0.1) with UL48-FKBP and UL103-FKBP in the presence and absence of 
Shield-1 and then analyzed by immunoblots at 24 and 120 hpi, using antibodies against 
representative immediate early (IE1 and IE2), early (UL44), and late (pp28/UL99) viral 
proteins.  GAPDH was used as a loading control. 
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Figure 10. Effects of regulated protein degradation on cVAC biogenesis.  Cells 
were infected with the indicated viruses in the presence or absence of Shield-1 for 120 
hr and then stained for cellular markers of the cVAC (cytoplasmic staining) and infection 
(IE2, nuclear staining).  Shield-1 had no effect on assembly complex development for 
the parental virus, whereas destabilization of pUL48 and pUL103 led to dispersal of 
early/recycling endosomes, and absence of the characteristic Golgi ring. 
50 
 
 
 
 
 
Figure 11. Relative abundance of regular vs irregular cVAC structures in the 
presence and absence of Shield-1.  Regular structures displayed circular Golgi rings 
and a concentration of EEA1-positive vesicles inside the rings. Irregular structures had 
fragmented or abnormal Golgi shapes, and/or dispersal of EEA1-positive vesicles.  
Statistical significance was measured using the Chi Square test (***, p<0.0001). n, 
number of cells counted. 
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Figure 12. Growth properties of recombinant extracellular viruses in the presence 
and absence of Shield-1.  (A) Replication of UL48-FKBP.  (B) Replication of UL103-
FKBP and UL103-FKBP-V5.  Virus replication at high (MOI = 3) and low (MOI = 0.01) 
MOI (single step and multi-step growth curves, respectively) in presence or absence of 
Shield-1.  +, cells infected in the presence of Shield-1; -, cells infected in the absence of 
Shield-1.  Virus titers were determined in triplicate; the standard errors are too small to 
be seen in the graphs. 
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Figure 13. Plaque sizes of UL103 recombinant viruses in the presence and 
absence of Shield-1 at 10 dpi.  Plaque size (area) = mm2 +/- SEM, as measured from 
photographs by using ImageJ (NIH) (128).  In the absence of Shield-1, UL103-FKBP 
plaque sizes were significantly smaller than for the other three conditions (t test, p < 10-
5). 
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Figure 14. Comparison of regular vs. irregular virions inside infected cells in the 
presence or absence of Shield-1. Regular virions contain DNA and an envelope. 
Irregular virions are in the process of envelopment or display an abnormal structure. 
Statistical significance was measured using the Chi Square test (*, p < 0.1; ***, p < 
0.0015). n, indicates the amount of viral particles counted.  
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CHAPTER THREE 
VIRAL AND CELLULAR INTERACTION PARTNERS OF pUL103 
Introduction 
Human cytomegalovirus (HCMV) induces a wide range of profound modifications 
of host cell biology, including changes in cell morphology, cell cycle, metabolism, 
intrinsic and innate immunity, and the endosecretory machinery.  Alterations in the 
endosecretory machinery include remodeling of the Golgi and early endosomal 
compartments to form the cytoplasmic virion assembly compartment (cVAC), where the 
mature tegument is acquired, secondary envelopment occurs, and vesicles containing 
mature virions are transported to the plasma membrane for release. 
cVAC biogenesis is contingent on the expression of specific HCMV miRNAs and 
late genes (105). Previously, we identified pUL48, pUL94, and pUL103 as being 
important for cVAC biogenesis (129). When pUL103 is degraded during infection, the 
cVAC does not form properly. pUL103 is a tegument protein that is conserved across 
the Herpesviridae (HSV UL7 homolog)(Table 1). pUL103 and its homologs are 
important for efficient production of infectious virions at low and high MOI.  Ahlqvist and 
Mocarski, as well as our lab, have identified roles of pUL103 in cell-to-cell spread, virion 
envelopment and egress (58, 129). The mechanisms employed by HCMV pUL103 and 
its relatives remain elusive.   
Identification of protein-protein interactions can provide insights into the activities 
of pUL103 during infection. Four HCMV proteins (pUL22, pUL48, pUL71, and pUL103) 
were previously identified as pUL103 binding partners. In a yeast two-hybrid analysis 
interactions were detected between pUL103 and itself, pUL22A, and pUL48N (120). An 
interaction between pUL103 and pUL71 was identified by co-IP and bimolecular 
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fluorescence complementation in uninfected cells (70). However, none of these 
interactions were confirmed in the context of HCMV infection. During HSV-1 infection, 
proper localization and incorporation into the virion of pUL7 (the HSV pUL103 homolog) 
is dependent on its interaction with pUL51 (homolog of HCMV pUL71) (88). In addition, 
HSV-1 pUL7 binds to the mitochondrial protein adenine nucleotide translocator (ANT2), 
an interaction of uncertain significance (82). Viral and cellular binding partners of 
pUL103 have not been studied in HCMV infected cells, leaving a void in understanding 
the biological roles and mechanisms of pUL103. 
To address this gap, we employed a set of complementary proteomics 
approaches that employed co-IP and proximity biotinylation (BioID) to identify viral and 
cellular proteins that interact with pUL103. Co-IP and the BioID system are well-suited 
for detection of interactions that are strong and direct. The BioID system also enables 
detection of weak, indirect, and transient interactions. The differences in these 
complementary methods provide internal controls that reduce the number of false 
positives, and interactions highly enriched in both approaches are more likely to be 
specific. Using these methods, we identified multiple novel interactions with viral and 
cellular proteins.  pUL103 interacted with several cellular antiviral proteins, including 
IFI16, and interacts with DNA-associated proteins and is present in nuclei.  We also 
found that pUL103 binds to ALIX (a component of the ESCRT machinery) via a novel 
ALIX-binding site, a role for pUL103 in the redistribution of ALIX to the cVAC, and that 
deletion of the ALIX binding site had a dominant negative effect on HCMV replication.   
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Materials and methods 
Cell culture and virus stocks.  Human foreskin fibroblasts (HFFs) below 
passage 20 were grown in Dulbecco modified Eagle medium (HyClone-Thermo Fisher 
Scientific, Waltham, MA) supplemented with 10% fetal bovine serum, 2 mM GlutaMAX 
(Life Technologies, Grand Island, NY), and 1% minimal nonessential amino acids 
(HyClone-Thermo Fisher Scientific, Rockford, IL). Virus stocks were propagated by 
infecting 80% confluent HFFs at an MOI of 0.01 and collecting supernatant every 4 
days. Virions present in cell culture supernatants were purified by centrifugation at 2700 
rpm for 15 min to remove cell debris, and then ultracentrifugation (70,000 x g for 1 h) 
through a 20% sorbitol cushion. Pelleted virions were resuspended and stored at -80ºC 
in DMEM containing 10% FBS. Titers of virus stocks were determined by plaque assay 
on confluent monolayers.  
Plasmids. All cloning was performed in Escherichia coli DH5α. To construct the 
BioID-UL103 plasmid (p), full length UL103 was amplified from pAD/Cre (primers listed 
in Table 2) and inserted into the pcDNA3.1 mycBioID (Addgene, Cambridge, MA 
plasmid #35700) (130) using XhoI and Aflll. UL103-V5-His(v) described in the following 
section was used to generate UL103-V5-His(p) by inserting the V5-His-tagged UL103 
gene into pcDNA3.1 between the KpnI and XbaI sites. Alanine substitutions and 
deletion mutants were created by overlap extension PCR, followed by incorporation into 
UL103-V5-His(p).   All constructs were verified by DNA sequencing. 
Recombinant viruses (BioID and V5-His).  Viruses were constructed by 
recombineering using the HCMV AD169 bacterial artificial chromosome pAD/Cre (kindly 
provided by Dong Yu) in SW105 cells (provided by the Court lab at the National Cancer 
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Institute). The UL103-V5-His and UL103-BioID mutants were created by inserting a 
gene cassette at the extreme c-terminus of UL103. The GalK/Kan cassette was PCR 
amplified from pYD-C630 (provided by Dong Yu) using 70-bp primers, 20-bp of which  
corresponded to flanking sequences in pYD-C630 and the remaining 50-bp were 
homologous to sites upstream and downstream of the UL103 stop codon (Table 2). 
Induction of the lambda RED recombinase in SW105 cells harboring pAD/Cre and the 
gene cassette lead to homologous recombination followed by selection of transformed 
colonies on LB-plates containing kanamycin. Single colonies were screened by BAC 
digestion and PCR.  
To construct the scarless UL103-V5-His or UL103-BioID mutants, the GalK/kan 
cassette was replaced by homologous recombination with another cassette containing 
V5-His or BioID and the homologous ends described above (Table 2). SW105 cells 
carrying UL103 with the replacement cassette were negatively selected for on 2-deoxy-
galactose (DOG) minimal plates. Galactose negative colonies were streaked on 
MacConkey agar plates supplemented with chloramphenicol and galactose. Non-
fermenting colonies were picked and screened by BAC digestion, PCR, and open 
reading frame sequence analysis.  
Co-Immunoprecipitation (co-IP).  Cells (approximately 3.0x107) were either 
transfected with 30 µg of plasmid or inoculated at an MOI of 0.1.  Transfected cells were 
harvested after 48 hr, and infected cells were harvested 5 dpi using  
radioimmunoprecipitation assay (RIPA) buffer (10 mM HEPES [pH 7.4], 1% sodium 
deoxycholate, 1X protease inhibitors [Roche, Indianapolis, IN], 150 mM NaCl, 1% 
Nonidet P-40, 0.1% SDS). Protein was extracted by passing the lysate through a 27 
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gauge needle 10 times, centrifuging at 13,000 rpm for 10 min, and collecting the 
supernatant. Antibodies were conjugated to the beads by mixing 20 µl of protein A/G 
Plus Agarose (Santa Cruz Biotechnology, Dallas, Texas) and 1 µg of antibody in 0.5 ml 
of PBS at 4°C overnight. Antibody-bead complexes were washed twice in PBS and then 
incubated with cell lysates overnight at 4°C in a tube rotator. Non-specific interactions 
were stripped from the immunocomplex by washing three times with RIPA buffer. For 
mass spectrometry analysis, beads were spun at 2000xg and resuspended in 50 µl of 
50 mM ammonium bicarbonate. For binding partner verification, immunocomplexes 
were washed with PBS, and the pellet was resuspended in 30 µl of 2X Laemmli sample 
buffer for immunoblot analysis.  
BioID.  Transfected and infected cells were incubated with 50 µM biotin 24 hours 
prior to harvesting. Cells lysed as described above were incubated at 4°C overnight with 
500 µl of streptavidin conjugated to magnetic beads (New England Biolabs, Ipswich, 
MA). Beads were washed once in 1.5 ml of wash buffer 1 (2% SDS in dH2O), once with 
wash buffer 2 (0.1% deoxycholate, 1% Triton X-100, 500 mM NaCl, 1 mM EDTA, and 
50 mM Hepes, pH 7.5), once with wash buffer 3 (250 mM LiCl, 0.5% NP-40, 0.5% 
deoxycholate, 1 mM EDTA, and 10 mM Tris, pH 8.1), and then twice with wash buffer 4 
(50 mM Tris, pH 7.4, and 50 mM NaCl). To evaluate sample integrity, 10% of the total 
was retained for immunoblots. The remaining beads were spun at 2000xg and 
resuspended in 50 µl of 50 mM ammonium bicarbonate for mass spectrometry.  
Mass spectrometry.  Samples were digested overnight using sequencing-grade 
trypsin (Promega) in 25 mM ammonium bicarbonate and 10% acetonitrile. The resulting 
peptides were separated by reverse phase chromatography (Acclaim PepMap100 C18 
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column, Thermo Scientific), followed by ionization with the Nanospray Flex Ion Source 
(Thermo Scientific), and introduced into an Orbitrap FusionTribrid mass spectrometer 
(Thermo Scientific). Primary data analysis was done using Proteome Discoverer 1.4 
(Thermo), which incorporated the Mascot (Matrix Science) algorithm.  Mascot searched 
the SwissProt_2014_06 and UniProt_Hum_Compl_All database for viral and cellular 
proteins respectively. Secondary analysis was performed with Scaffold 4.3.4 (Proteome 
Software) set to a minimum protein identification probability of ≥99% and 2 cellular or 3 
viral unique peptides at ≥99% minimum peptide identification probability. Proteins 
identified by Scaffold were normalized by size using the normalized spectral abundance 
factor (NSAF) (131). Non-specific cellular interactions were filtered out using the 
contaminant repository for affinity purification (CRAPome) (132). 
Cell Fractionation. HFFs were collected and pelleted in ice cold PBS. Following 
pellet resuspension in 900 µl of mild lysis buffer (0.1% NP40 in PBS), 300 µl were 
removed as whole cell lysate. Remaining cell lysate was centrifuged for 10 seconds. 
300 µl of the supernatant was removed as the cytoplasmic fraction, while the pellet was 
washed in 1 ml of lysis buffer followed by another 10 seconds spin to pellet the nuclear 
fraction. The nuclear pellet was resuspended in 180 µl of 1X SDS-Laemmli buffer. 
Whole cell lysates and nuclear fractions were sonicated prior to immunoblots. 
Immunoblots.  Protein was quantified by bicinchoninic acid (BCA) assay (Pierce 
Biotechnology, Rockford, IL). For cell lysates, 50 µg of protein was solubilized in 2X 
SDS-Laemmli buffer followed by SDS-PAGE. Separated proteins were transferred to 
nitrocellulose membranes (Whatman, Florham Park, NJ), probed with primary 
antibodies, and then reacted with HRP-conjugated goat anti-mouse/rabbit IgG 
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secondary antibodies (Thermo Scientific, Rockford, IL). Reactions were detected with 
the Supersignal West Pico Chemiluminescent substrate (Bio-Rad, Hercules CA) on 
autoradiography film (GE Healthcare, Pittsburgh, PA). Antibodies are listed in Table 3. 
Immunofluorescence assays (IFA).  HFFs were seeded at 80% confluency one 
day prior to infection on 0.2% gelatin-coated 8-well glass chamber slides (Thermo 
Fisher Scientific, Waltham, MA). The following day, cells were infected at an MOI of 0.1 
and then fixed in paraformaldehyde and stained at 120 hpi as previously described 
(129). Primary antibodies are listed in Table 3.  Fluor-tagged secondary antibodies 
(Alexa Fluor 488-conjugated goat anti-rabbit IgG and Alexa Fluor 568-conjugated goat 
anti-mouse IgG) were from Life Technologies (Grand Island, NY). Mounting was done 
with Vectashield containing DAPI (4’,6-diamidino-2-phenylindole) (Vector Laboratories 
Inc., CA). Imaging was done on a Nikon E800 fluorescence microscope and a Leica 
TCS SP5 laser scanning confocal microscope. 
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Results 
Experimental design.  Affinity purification followed by mass-spectrometry can 
be used to identify proteins pulled-down by a bait protein. The proteins identified can be 
true interacting partners, but false positives are common, arising due to reasons that 
can include non-specific interactions with the beads, antibody, protein tag, and sticky or 
highly abundant proteins.  To increase the likelihood of identifying biologically 
meaningful interactions, we limited confounding by false positives through the use of  
two independent methods of affinity purification:  co-immunoprecipitation (co-IP) and 
proximity labeled biotinylation (BioID). Co-IP detects proteins that strongly interact with 
the bait protein, while the BioID system uses BirA*, a promiscuous biotin ligase that 
biotinylates proteins within ~10 nm of the tagged protein (130). Each method uses 
different beads, antibodies, tags, and binding/elution conditions. The differences in 
these complementary methods provide internal controls that reduce the number of false 
positives, while proteins highly enriched in both approaches are more likely to be 
specific.  
As shown in Table 4, experiments involved plasmids (p) and recombinant viruses 
(v) with tags fused to pUL103. Plasmids included one construct that expresses the BirA* 
protein alone, one with BirA* fused to the pUL103 N-terminus (BioID-pUL103(p)), and 
one in which the V5-His tag was added to the C-terminus of pUL103 (UL103-V5-His(p)). 
Two recombinant viruses were also used, in which the tags were attached to the C-
terminus of pUL103 (UL103-BioID(v) and UL103-V5-His(v)). For infection experiments, 
we inoculated cells at an MOI of 0.1 with either UL103-V5-His(v) or UL103-BioID(v) and 
harvested the cells 5 days post infection. A low MOI infection allows simultaneous 
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analysis of cells at multiple stages of infection, giving us a broad overview of the viral 
and cellular proteins that interact with pUL103.  
Collectively, these constructs and conditions enable identification of interactions 
of pUL103 with cellular proteins in the absence of other viral proteins, with HCMV 
proteins in infected cells, with cellular proteins in infected cells, and with cellular proteins 
enhanced during infection. 
Effect of tags on virus replication, expression, and localization of pUL103. 
To determine if the affinity tags influenced the localization or activity of pUL103 we 
conducted immunofluorescence and virus replication plaque assays. In transfected 
cells, UL103-V5-His(p) and BioID-UL103(p) were abundant in perinuclear regions that 
correspond to ER and Golgi structures (Fig. 15A), while BioID(p) alone was dispersed 
diffusely throughout the cell cytoplasm (data not shown). During infection, UL103-V5-
His(v) and UL103-BioID(v) localized to the assembly compartment, consistent with 
previous reports (Fig. 15A) (58, 129). In multi-step growth experiments, UL103-BioID(v) 
produced titers similar to the parent, while UL103-V5-His(v) replication was delayed, 
taking 6 days to reach parental levels (Fig. 15B). Our previous results using an FKBP 
tag also showed a lag in extracellular virus production, suggesting that some tags at the 
extreme C-terminus of pUL103 perturb virion production at earlier times after infection 
(129). Neither tag had a discernable effect on pUL103 localization or production of 
infectious progeny at late stages of viral replication.  
Viral proteins identified by AP-MS.  Mass spectrometry returned 5566 total 
viral spectral hits, which correspond to 49 HCMV proteins using co-IP and 47 proteins 
with BioID (outlined in Fig. 16A). Altogether, 53 viral proteins were identified, which 
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indicates high overlap using both methods. Larger proteins tend to generate higher 
spectral counts than smaller proteins, so we used the normalized spectral abundance 
factor (NSAF) to normalize the HCMV proteins based on size. To determine the most 
significant interactions, the HCMV proteins displaying an NSAF greater than 0.5 were 
plotted on a UL103-BioID vs UL103-V5-His graph (Fig. 16B). The highest NSAF values 
were seen for pp65 (21.6 UL103-BioID and 23.4 UL103-V5-His), but pp65 was also 
pulled down in untagged AD169 control lanes indicating a non-specific interaction (data 
not shown). The second highest NSAF value for UL103-V5-His was pUL103 
(NSAF=13.25), demonstrating sufficient immunoprecipitation of the pUL103-V5-His 
protein with the V5 antibody. The tegument hub protein, pUL25 was also highly 
abundant in both approaches (6.7 UL103-BioID and 4.0 UL103-V5-His), but lack of a 
pUL25 specific antibody prohibited further verification. Other proteins enriched were 
pUL44, pUL112/113, pUL84, pUL71, pUL50, pUL45, pUL86, IE2, pUL34, pUL47, and 
pUL56. The identification of pUL71 by our pull-downs as well as Fischer and Mertens in 
transfected cells, provides validity to our dual method approach and evidence that 
pUL103 interacts with pUL71 during infection (70). In addition, Roller and Fetters 
showed that the homologues of pUL103 and pUL71 (HSV pUL7 and pUL51) form a 
complex in HSV1 infected cells (88).  
Verification of interactions with viral proteins.  We detected many previously 
unidentified pUL103 viral binding partners (Fig. 16B). The properties of the highest 
scoring viral proteins revealed many to be DNA associated (pUL34, IE2, pUL44, pUL84, 
etc.). This was surprising, since our lab and others have shown pUL103 
immunofluorescence staining to be strictly cytoplasmic in infected cells (58, 129) (Fig. 
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15A). Nonetheless, the HSV1 and HSV2 homologs of pUL103 (HSV pUL7) can be 
present in nuclei (82, 89). To assess the nuclear presence of pUL103 we performed 
three-dimensional confocal microscopy on HCMV infected cells. Although much less 
intense than the cytoplasmic fluorescence, in central slices of the z-series 
(approximately equidistant from apical and basal surfaces), weak, but unambiguous 
nuclear staining for pUL103 was present in nuclei (Fig. 17A). We also performed cellular 
fractionation followed by western blots and found that pUL103 is present in the nuclear 
fractions of cells (Fig. 17B). 
We employed immunoprecipitation and immunoblotting to verify interactions of 
pUL103 with three of the DNA associated viral proteins (IE2, UL34, and UL44). IE2 and 
pUL34 were verified by pull-downs with a V5 antibody followed by immunoblotting. Each 
blot showed a band in the UL103-V5-His IP lane, but not in the parent or control lanes 
(Figs. 17C and 17D). pUL44 is approximately 46 kDa and is obscured by the 50 kDa 
heavy chain antibody band. Because of this, pUL103-V5-His was immunoprecipitated 
with a pUL44 antibody and then probed with anti-His. There was a clear band in the 
UL103-V5-His (Fig. 17C, lane 3) that co-migrates with pUL103 in the total cell lysates 
(Fig. 17C, lane 6). These results provide evidence for the specificity obtained by 
merging results obtained with two independent affinity-based pull-down approaches, 
and revealed novel interactions of pUL103 with IE2, pUL34 and pUL44.  
Interactions of pUL103 with cellular proteins.  We used the dual affinity 
purification approach to identify the binding partners of pUL103 in transfected and 
HCMV infected cells. Mass spectrometry detected a total of 2953 cellular proteins pulled 
down by both methods. As mentioned previously, the NSAF formula was applied for 
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spectral count normalization. Our initial mass spectrometry dataset included proteins 
(tubulins, actins, ribosomal, and mitochondrial) that were abundant in the BioID-
UL103(p) control or had high CRAPome scores, indicating non-specific interactions. To 
eliminate background, we only considered proteins that had a UL103-BioID(v) NSAF 
value higher than the NSAF of the BioID(p) control, and a CRAPome score lower than 
100. We utilized two methods of analysis; NSAF to identify all the cellular protein 
interactions (Fig. 18A) and NSAF fold-change of infected cells versus uninfected cells to 
detect interactions enhanced during infection (Fig. 18C). Stringent cutoffs of 3 and 2 
were used for NSAF and for NSAF fold-change, respectively, to identify pUL103 binding 
partners that are potentially of biological significance (Fig. 18B and 18D). A total of 13 
cellular proteins met these criteria, with 6 being shared between both analyses (Table 5 
and Figs. 18A and 18C). 
Among the highly enriched proteins are several involved in innate immune 
responses (IFI16, STAT1, ISG15, MYD88, and IFIT1). All of these antiviral proteins had 
low NSAF scores or were undetected in transfected cells, thus the interactions might be 
attributed to elevated protein expression in infected cells. However, the mRNA levels of 
IFI16 decreased by 71% and 62% in fibroblasts infected for 96 hours with HCMV strains 
Towne and AD169 (133); a similar decrease is evident in immunoblots of infected cell 
lysates (Fig. 19A). Importantly, the IFI16 interaction was verified by forward and reverse 
co-IP, suggesting a novel role for pUL103 in the regulation of innate immune signaling 
during infection (Fig. 19A).  
Another category of proteins identified in these analyses includes proteins 
involved in formation and trafficking of vesicle (MYO1C, PDCD6IP, and COPB1), which 
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may interact with pUL103 during virion envelopment and egress. Pulldowns in 
transfected and infected cells confirmed the binding of pUL103 to the ESCRT-
associated protein, ALIX (Fig. 19B). Interestingly, amino acid motif analysis of pUL103 
revealed two potential “late” or “L” domains that bind ALIX at the C-terminus (Fig. 20A). 
ALIX binding domains are well-characterized motifs present in retrovirus gag proteins 
that are sites of interaction with ALIX important for virion budding at the plasma 
membrane (reviewed in (134)). These results led us to further explore the pUL103-ALIX 
interaction. 
Mutational analysis of ALIX binding motifs in uninfected cells. The amino 
acids YPNL at position 230 to 233 in pUL103 represent a type 1 late domain (134). The 
YPNL present in pUL103 corresponds to the YPXnL ALIX binding motif (X is any residue 
and n can range from 1 to 3). In non-normalized transfection experiments with single 
and multiple amino acid substitution of the YPNL motif had little effect on pUL103-ALIX 
interaction (Fig. 20B). 
Fifteen amino acids upstream of YPNL, is a sequence, GWPVGLGLL, that has 
properties that suggest it might serve as an ALIX site. The high similarity between 
tryptophan and tyrosine allow them to sometimes be interchanged, as seen in 
SIVwrcPbb Gag p6, in which the YPXL motif is replaced by WPXL (135). The 
GWPVGLGLL sequence thus conforms to both type 1(YPXnL) and type 3 (ΦYXnΦXnL) 
late domain motifs. In experiments in which levels of pUL103 were normalized relative 
to GAPDH, mutation of either of the putative pUL103 late domains led to at least 50% 
reduction in ALIX that was pulled down in uninfected cells (Fig. 19C). These results are 
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consistent with pUL103 containing two motifs together are important for its interaction 
with ALIX.  
Influence of pUL103 on ALIX localization. Given the involvement of ALIX in 
vesiculation events similar to those associated with secondary envelopment, we 
examined ALIX localization during infection. By IFA, ALIX was diffusely distributed 
throughout the cytoplasm of uninfected cells, but strongly localized to the cVAC at late 
times post infection (Fig. 21A). To assess the location of ALIX in the absence of 
pUL103, we used a UL103-FKBP-V5 virus that contains a regulatable destabilization 
domain attached to UL103 (129). In the presence of Shield-1, pUL103 was stabilized 
and abundant in the cVAC along with ALIX (Fig. 22A). Removal of Shield-1 reduced the 
amount of pUL103 and ALIX in the assembly complex by 34% and 56% respectively 
(3D quantification of at least 14 cells per condition). The effect on ALIX was not due to 
differential ALIX expression, as immunoblots showed that levels of ALIX were similar in 
mock infected cells and in cells infected with either the parental or V5-His-tagged UL103 
viruses, and regardless of whether the UL103-FKBP-V5 virus was treated with Shield-1 
(Fig. 21B). These results demonstrate that HCMV infection results in pUL103-regulated 
localization of ALIX to the cVAC.  
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Discussion 
HCMV pUL103 is a conserved herpesvirus tegument protein that is involved in 
several processes, including cell-to-cell spread, cVAC biogenesis, and virion 
envelopment and egress.  We identified its interaction partners to provide novel insights 
into its molecular functions and biological roles. Several pUL103 binding partners were 
identified in transfection and yeast two-hybrid systems, but none have been 
characterized in the context of infection (70, 120). HCMV infection induces profound 
changes in host cells, altering the localization, production, and function of cellular 
proteins. In addition, in the absence of infection, interactions among viral proteins, as 
well as interactions of viral proteins with cellular proteins (e.g., antiviral proteins) do not 
occur. To address these gaps, we infected cells with recombinant viruses that express 
forms of pUL103 that were tagged to enable independent forms of pull-downs (co-IP 
and BioID).  This was followed by mass spectrometry to identify interacting partners. By 
restricting our analysis to interactions that scored highly in both of the complimentary 
methods, we increased the likelihood of selecting specific, high-value biologically 
relevant interactions worthy of further study, while limiting the number of false positives 
and incidental interactions.  The set of viral and cellular binding partners we identified 
for pUL103 suggest that it, and possibly its homologs in other herpesviruses, interact 
with nuclear proteins that bind DNA, and play roles in the regulation of antiviral 
responses and in formation, transport, and targeting of intracellular vesicles.  The latter 
activities may be important during during cVAC biogenesis, and subsequently during 
secondary envelopment and egress.  
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Interactions of pUL103 with other HCMV proteins. The viral proteins that met 
our screening criteria belong to several distinct functional categories, including 
tegument proteins, DNA-binding proteins, and capsid and nuclear egress proteins. 
pUL103-pUL71 was previously shown to interact outside the context of infection in co-
transfection and bimolecular fluorescence complementation experiments (70), and 
interactions between the HSV homologs (pUL7 and UL51) of these proteins were 
detected in infected cells (88). Our detection of this interaction provides validation for 
our dual pulldown approach.  
Of the interactions that scored highly in both the V5 and BioID experiments, 
follow-up pull-down experiments were performed with antibodies against pUL34, pUL44, 
and IE2; in each instance, the interactions were detected only in cells infected with the 
UL103-V5-His virus, and not in mock infected cells or cells infected with untagged 
parental virus.  These results provide further evidence that the interactions 
characterized by high NSAF scores in both the V5- and BioID-based proteomic 
analyses are sufficiently specific to justify follow-up studies. 
The most prominent interaction with dual high NSAF scores was observed 
between pUL103 and the HCMV tegument protein pUL25. pUL25 is expressed at late 
times post infection, strongly localizes to the cVAC, and is incorporated into the three 
major types of virus particles: mature virions, noninfectious enveloped particles, and 
dense bodies (136, 137). The reported interactions of pUL25 with several other 
tegument proteins suggests it serves as an organizing hub for incorporating viral 
proteins into enveloped particles (120). Further analysis of the pUL103-pUL25 
interaction is warranted. 
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We did not detect the previously described interactions between pUL103 and 
HCMV pUL22A and pUL48N, which were identified in a yeast two-hybrid system but not 
verified by co-IP in transfected cells (120). In yeast cells, pUL103 may lack 
posttranslational modification(s) or have alternative folding that exposes or creates 
artificial binding sites. While we acknowledge their limitations, tagged recombinant 
viruses can provide useful representations of protein-protein interactions during 
infection. The specificity of such methods can be enhanced by screening on the basis of 
dual high positivity using co-IP and Bio-ID methods.  
Nuclear pUL103.  Identification of five viral DNA associated proteins with dual 
NSAF values above 0.5 (Fig. 16B) and the co-IP verification of three of these (pUL34, 
pUL44, and IE2), suggests a nuclear role for pUL103. This was unexpected given that 
pUL103 appears to be strictly cytoplasmic by IFA in HCMV infected cells. Only after 
substantially increased exposure times were we able to detect a faint but discernable 
pUL103 signal in nuclei (Fig. 17A). Immunoblots of fractionated cells confirmed the 
presence of pUL103 in the nuclear fraction. Nuclear pUL103 has also been described 
for the HSV homolog (pUL7), in which IFA and transmission immunoelectron 
microscopy analysis detected pUL7 in infected cell nuclei (88, 89). The function of 
nuclear pUL103 is unknown, but may involve a conserved domain, present in the 
pUL103 homologs of all members of the herpesviridae. The conserved domain is 
homologous with a segment of DNA topoisomerase III of Schizosaccharomyces pombe; 
this protein releases supercoil tension that is introduced during DNA replication and 
transcription (89, 138). The presence of this conserved domain, in conjunction with its 
71 
 
 
 
observed nuclear localization and interaction with HCMV DNA associated proteins 
suggests a heretofore undefined role for pUL103 in nuclear events.  
Interactions of pUL103 with cellular proteins.  Our interest at this stage is to 
identify interactions unique to pUL103 that are more likely to be of true biological 
significance.  Because of this, we applied the stringent screening criteria, described in 
the Results section and in Fig. 16A, understanding that we likely excluded some true 
interactions. For instance, HSV pUL7 can pull-down the mitochondrial protein, ANT2 
(82). We found a dual high scoring interaction between ANT2 and pUL103 in 
transfected and in infected cells, but because ANT2 has a CRAPome score of 223, it 
did not pass our screening filter.  Even though the interaction might be biologically 
meaningful, we did not pursue it here.   
Most of the proteins that passed our screening criteria are involved in innate 
antiviral responses and vesicle formation/trafficking (Fig. 18A). A cellular protein from 
each category was verified in reciprocal pull-down experiments, providing evidence that 
these represent true interactions.   
A novel role for pUL103 in innate immunity? A possible role for pUL103 in 
regulation of innate immunity is difficult to evaluate in uninfected cells. With the 
exception of STAT1, none of the antiviral interaction partners were detected in our 
transfection experiments. In infected cells, the presence of pathogen-associated 
molecular patterns (PAMPs) activates the antiviral response. Relocalization, increased 
expression, or phosphorylation can lead to interactions with viral binding partners. We 
identified four antiviral proteins that displayed dual high NSAF scores and verified the 
interaction with IFI16 by reciprocal co-IP. The abundance of antiviral proteins detected 
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demonstrates that pUL103 is capable of interacting with and modulating the innate 
immune response either directly or indirectly.  
We did our proteomic experiments after low moi infections (moi - = 0.1).   In 
addition to cells at the late stage of infection, at the time of harvest (5 dpi), the cultures 
would have included non-synchronously infected cells at the earliest stages of infection.  
We were thus able to sample material from various stages of infection.  Virion tegument 
proteins are introduced into the host cell immediately upon fusion of the viral and host 
cell membranes. The release of tegument proteins pp65 and pp71 into host cells are 
known to be critical for subverting the innate immune response and helping to establish 
an environment conducive to productive infection (139, 140). pUL103 is a virion 
associated tegument protein and may have a similar function when engaging antiviral 
proteins (54). In addition, virion associated and newly synthesized pUL103 could 
interact with antiviral proteins to facilitate cVAC biogenesis. Recent work by Xie and 
colleagues showed that HCMV makes use of interferon-induced transmembrane 
proteins (IFITMs) for cVAC assembly and virion production (71). The biological role of 
the pUL103 interaction with antiviral proteins is being assessed.  
Potential roles for pUL103 in biogenesis and trafficking of intracellular 
vesicles.  Identification of three proteins (COPB1, MYO1C, and ALIX) involved in 
formation and trafficking of vesicles suggests a connection to the known role of pUL103 
in virion envelopment and egress. The COPB1 mediates Golgi fragmentation during the 
M-phase of the cell cycle and retrograde transport from the Golgi to the ER (141, 142). 
MYO1C is involved in trafficking GLUT4 to the plasma membrane, and participates in 
lipid raft organization (143-145). These cellular proteins have functions that encompass 
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activities of the sort that would be involved in cVAC biogenesis and trafficking of virions 
to the cytoplasmic membrane, a subject for future study.  
The specificity of the pUL103-ALIX interaction was demonstrated by a 
combination of dual high NSAF scores using both proteomic approaches, a low 
CRAPome score for ALIX, NSAF scores higher for pUL103 pull-downs than for free 
BioID, pull-downs in cells transfected with pUL103-V5-His, and positive pull-downs in 
cells infected with UL103-V5-His(v) but not with the untagged parental virus. Proteins 
that bind to ALIX typically interact via ALIX-specific late domains that are important for 
virion production in many RNA and DNA viruses (146-150). Late domains in retrovirus 
gag proteins can bind the V domain of ALIX to facilitate viral budding at the cell 
membrane (reviewed in (134, 149, 150)). For DNA viruses, vaccinia viruses use an 
ALIX binding domain for extracellular virion production, and Epstein-Barr virus, a 
gammaherpesvirus, exploits ALIX for vesicle formation and nuclear egress of capsids 
(146, 148). The use of ALIX and ESCRT machinery is thus a common theme for virion 
production for many viruses. 
By sequence analysis, we identified two adjacent ALIX-binding motifs in pUL103, 
one that conforms to canonical Type1 and Type 3 motifs, and one that matches the 
Type 1 motif (Fig. 20A).  We evaluated mutations in these motifs in pull-down 
experiments, and found that changes in the Type 1 motif had little effect by themselves, 
while deletion of the Type1 or 3 motif or substitution of five critical residues with 
alanines led to >60% reduction in the amount of ALIX pulled down by pUL103-V5-His.   
Our identification of two adjacent ALIX binding domains in HCMV pUL103 and 
the strong infection and pUL103 influenced or induced localization of ALIX to the cVAC 
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during infection suggest involvement of ALIX in HCMV envelopment and egress, 
perhaps during secondary envelopment.  However, siRNA knockdown and dominant 
negative versions of ALIX had no effect on HCMV virion production (48, 78). This raises 
the possibility that HCMV employs redundant ESCRT-related pathways during the late 
stages of virion biogenesis.  Recombinant viruses with altered pUL103 ALIX binding 
domains are under construction to enable elucidation of the role of the pUL103-ALIX 
interaction during infection. 
A major challenge for identification of interacting partners is the abundance of 
false-positives that are typically observed. To address this, we employed parallel 
analysis of interacting partners pulled down using two affinity based methods (V5-His 
and BioID). By coupling dual high NSAF cutoffs with other stringent selection criteria we 
effectively screened for high value interactions. Detection of the previously identified 
pUL71 interaction, and verification of pUL44, IFI16, and ALIX interactions by reverse co-
IP, indicates our screening process selected for biologically plausible interactions. The 
collection of viral and cellular proteins identified provides novel insights into the 
biological functions of pUL103 and its respective homologs. This provides a robust 
foundation for future studies.  
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Table 9. Antibodies used in IFA and immuoblot assays 
Antibody Target Host/isotype, clone Source, catalog no. 
Epitope tag   
V5 (14 amino acids) Mouse monoclonal/IgG2a  Life Technologies, R960-25 
His (6 amino acids) Rabbit polyclonal  Rockland 600-401-382 
   
Cellular   
GAPDH (36 kDa) Mouse monoclonal/IgG1, clone GA1R Thermo Scientific, MA5-15738 
GM130 (130 kDa) Mouse monoclonal/IgG1(κ), clone 35/GM130 BD Biosciences, 610822 
EEA1 (180 kDa) Rabbit polyclonal Abcam, ab2900 
IFI16 (85-95 kDa) Mouse monoclonal/IgG1, clone 1G7 Santa Cruz, sc-8023 
Myo18A (230,190 kDa) Mouse monoclonal/IgG1, clone H-10 Santa Cruz, sc-365328 
ALIX (96 kDa) Rabbit polyclonal Abcam, ab76608 
   
HCMV   
IE1 and IE2 (IE1, 72 kDa;IE2, 86 kDa) Mouse monoclonal/IgG1(κ), clone CH160 Virusys, P1215 
IE2 (86 kDa) Mouse monoclonal, clone 8B1.2 Chemicon (millipore), MAB810 
pUL44 (CMV ICP36), 46 kDa Mouse monoclonal/IgG1(κ), clone 10D8 Virusys, CA006-100 
UL34-R4 Rabbit polyclonal Bonita Biegalke (Ohio 
University)  
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Table 10. Constructs and experiment conditions 
Constructs Condition Affinity ligand Beads 
BioID(p) Transfected Streptavidin Magnetic  
BioID-UL103(p) Transfected Streptavidin Magnetic  
UL103-BioID(v) Transfected Streptavidin Magnetic  
UL103-V5-His(p) Infected V5 Agarose A/G 
UL103-V5-His(v) Infected V5 Agarose A/G 
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Figure 15. The effect of tagged pUL103 on localization and viral growth. (A) HFFs were 
either transfected (p) for 48 hours or infected (v) at an MOI of 0.2 for 120 hours, then analyzed 
by fluorescence microscopy. pUL103 was visualized using a V5 antibody against the V5-His 
epitope or a myc antibody targeting the BioID tag. (B) Replication of UL103-V5-His and UL103-
BioID recombinant viruses were evaluated by multi-step growth curves (MOI=0.1). Virus titers 
were performed in triplicate.  
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Figure 16. Experimental scheme and graphical representation of enriched HCMV 
proteins. (A) HFFs were infected for 120 h at an MOI of 0.1 with UL103-V5-His(v) or 
UL103-BioID(v) and immunocomplexes were pulled-down with antibodies to V5 or biotin 
respectively. Mass spectrometry spectral counts were normalized based on size using 
the normalized spectral abundance factor (NSAF) formula. (B) Scatter plot of viral 
protein NSAFs from co-immunoprecipitation and proximity labeled biotinylation 
experiments. The dotted line separates the viral proteins with an NSAF > 0.5 (colored) 
from those less enriched (gray). Asterisk (*) indicates a known interaction. (C) Bar graph 
of all the viral proteins identified at increasing NSAF thresholds. The stripes indicate 
proteins shared by both methods. 
82 
 
 
 
 
Figure 17. Localization of pUL103 in infected cells and co-immunoprecipitation 
verification of viral proteins. (A and B) HFFs were infected with UL103-V5-His(v) for 
96 h at an MOI of 0.1 and probed with anti-V5 antibody. (A) The pUL103-V5-His tagged 
protein was analyzed by confocal microscopy. The center slice of a z-stack is shown 
with the nuclei outlined using ImageJ. (B) Cellular fractionation of infected cells using 
antibodies against UL44 and GAPDH to determine nuclear (N) and cytoplasmic (CY) 
fractions respectively. (C and D) Pull-downs were performed with anti-UL44 or anti-V5 
on HFFs infected for 120 h at an MOI of 0.1. The immunoprecipitating antibody (IP) and 
the probing antibody (IB) are listed to the left of each blot. Immunoblots were probed 
with antibodies against His tagged UL103, IE1/2, and UL34  
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Figure 18. Charts of the NSAF and NSAF fold change of cellular protein 
interactions. (A) After filtering out non-specific interactions, the cellular NSAF of the of 
UL103-V5-His(v) and UL103-BioID(v) was plotted against each other. The function of 
the most enriched interactions (NSAF >3) are shown. (C) NSAF fold change selects for 
cellular interactions enhanced during infection. Fold changes greater than 2 highlights 
multiple antiviral proteins. (B and D) Charts showing all the cellular proteins at 
increasing cutoff values. The stripes indicate proteins shared by both methods. 
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Figure 19. Co-immunoprecipitation verification of IFI16 and ALIX interactions. (A) 
HFFs were infected for 120 h at an MOI of 0.1 and affinity purification was conducted on 
the left three lanes while the right three lanes contain protein from cell lysates. The 
immunoprecipitating antibody (IP) and the probing antibody (IB) are listed to the left of 
each blot. pUL103 was purified with IFI16 in reciprocal pull down assays. (B) Affinity 
purification of pUL103 using a V5 antibody verified the interaction with ALIX in 
transfected and infected cells. 
  
85 
 
 
 
 
 
Figure 20. pUL103 amino acid sequence schematic and mutational analysis of late 
domains. (A) Map of HCMV pUL103 gene depicting a herpesvirus conserved region 
(GFX8EDX12R), along with HCMV specific helicase and late domains. (B and C) Co-
immunoprecipitations of pUL103 using a V5 antibody in transfected cells. (B) Alanine 
substitutions within the ALIX motif had little to no effect on the pUL103-ALIX interaction. 
(C) Alteration of the first or second ALIX binding motif reduced the quantity of ALIX 
pulled down with pUL103. (D) The quantity of ALIX immunoprecipitated per condition 
was measured by densitometry and divided by normalized pUL103. The amount of 
pUL103 produced was normalized by taking the ratio of GAPDH to pUL103.  
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Figure 21. ALIX redistribution during infection. (A and B) ALIX localization and 
proteins levels were detected in uninfected and infected HFFs (MOI of 0.1, 120 hpi) by 
IFA and immunoblot. (A) Infection enhances ALIX staining which overlaps cVAC 
markers. (B) The protein levels ALIX were unchanged with each condition.   
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Figure 22. ALIX redistribution involves pUL103. (A) The localization of ALIX during 
pUL103 regulation by the Shield-1 ligand. (B) 3D quantitation of ALIX mean 
fluorescence intensity in the cVAC relative to the parent (measured using ImageJ). A 
significant change was seen only in the presence and absence of pUL103. (C) The 
same cVAC area was used for 3D quantitation of pUL103 by mean fluorescence 
intensity. 
  
88 
 
 
 
 
Chapter Four 
Conclusions and Discussion 
Human cytomegalovirus (HCMV) infection has multiple effects on host cells, 
including remodeling the cytoplasm to form the cytoplasmic virion assembly complex 
(cVAC), the site of final virion assembly. The HCMV genes specifically responsible for 
initiating and regulating cVAC biogenesis have not been defined.  Our work set out to 
determine which HCMV genes are involved in this process. Previous work in our lab 
described the three dimensional structure of the cVAC using cellular markers against 
Golgi, trans-Golgi and early endosomes components. These cellular markers were used 
as indications of proper cVAC development. An siRNA screen targeting 26 early-late 
and late genes identified three HCMV genes (UL48, UL94, and UL103) whose silencing 
had major effects on cVAC development. To ensure the protein product of these genes 
is specifically involved; we created two recombinant viruses with a protein 
destabilization tag attached to UL48 or UL103. Degradation of either protein resulted in 
the disrupted cVAC assembly, validating the siRNA results. The set of viral genes 
identified is by no means all-encompassing as other immediate early or early genes 
were not included in our analysis. 
It is important to note, that all three proteins involved in cVAC biogenesis are 
tegument proteins incorporated into mature virions (54). Tegument proteins introduced 
into host cells upon entry may facilitate cVAC development, yet whether these proteins 
play a role during early or late stages of infection has yet to be addressed. The 
incomplete degradation of these proteins using the FKBP destabilization domain has 
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prevented these types of analyses. However, the partial degradation of pUL48 and 
pUL103 is sufficient to disrupt cVAC formation, suggesting that wild-type expression 
levels are necessary for efficient virion production.   
In addition to cVAC biogenesis, pUL103 is a highly conserved, multifunctional 
herpesvirus tegument protein involved in several processes, including cell-to-cell spread 
and virion envelopment and egress. To further understand the mechanisms of action 
and predict additional functions of pUL103, we sought to identify its interaction partners. 
To do so, we employed two complementary methods, co-immunoprecipitation (co-IP) 
and BioID, to detect viral and cellular proteins that interact with pUL103 in uninfected 
and HCMV infected cells. Our approach identified a multitude of pUL103 binding 
partners. To identify interactions of potentially high value, we selected for interactions 
highly abundant in both approaches and applied stringent selection criteria. The viral 
and cellular proteins that passed our selection criteria are associated with DNA, the 
antiviral response, and the biogenesis and transport of cytoplasmic vesicles.  
Analysis of some of these interactions expanded our current understanding of the 
pUL103 multifunctional repertoire; we detected HCMV pUL103 in nuclei of infected 
cells, identified two functional ALIX binding domains, and established a role for pUL103 
in ALIX localization during infection. This provides novel insights to the biological 
functions of pUL103 that may also be exercised by its homologous herpesvirus 
counterparts.  
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 Human cytomegalovirus (HCMV) is a large double-stranded DNA virus that 
causes severe disease in newborns and immunocompromised patients. During 
infection, HCMV is able to reconfigure the host cell machinery to establish a virus 
producing factory, termed the cytoplasmic virion assembly complex (cVAC). Generating 
drugs that affect cVAC development or function provides an alternative mode of action 
for HCMV antivirals that can essentially eliminate virion production. The objective of this 
work is aimed at identifying regulators of cVAC biogenesis that may serve as potential 
drug targets.  
We identified three HCMV genes (UL48, UL94, and UL103) whose silencing or 
protein degradation had major effects on cVAC development, including failure to form 
the Golgi ring and dispersal of markers of early and recycling endosomes. In addition, 
we found that mutant viruses expressing an unstable form of the UL103 protein causes 
a reduction in plaque size and the aberrant formation of intracellular virions. 
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To help define the mechanisms of action and predict additional functions of 
pUL103, we investigated its viral and cellular protein-protein interactions. We applied a 
dual method approach, co-immunoprecipitation and proximity biotinylation affinity 
purification followed by mass spectrometry to enrich for pUL103 interaction partners in 
uninfected and HCMV infected cells. This led to identification of pUL103 in nuclei, 
delineation of a novel ALIX binding domain, and a role for pUL103 in ALIX localization in 
infected cells.  
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